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Significance of Chapters 
 
The chapters included in this thesis by publication provide an insight into the use of zebrafish 
as a model to aid in drug discovery and a suitable model for in vivo toxicity testing. 
Furthermore, it demonstrates how zebrafish as a model are useful in understanding lipid 
biology and metabolism under chemical modulation.  
Chapters 2 and 3 both investigate how a new class of organic solvents can be utilised to aid in 
drug discovery. Chapter 2 “A study on acute toxicity and solvent capacity of solvate ionic 
liquids in vivo using a zebrafish model (Danio rerio)” investigates the toxicity profile of novel 
organic solvents aptly termed solvate ionic liquids. SILs have been proposed to be used as a 
suitable replacement to the more common solvent DMSO, as DMSO is currently the widely 
used solvent to deliver small compounds and drugs both in vivo and in vitro.  
Following on from the study conducted in chapter 2, chapter 3 “Comparison of Solvate Ionic 
Liquids and DMSO as an in vivo delivery and storage media for small molecular therapeutics” 
elucidates the capacity and efficacy of the SILs being investigated to deliver small compounds 
in vivio compared to the capacity of DMSO at concentrations found in chapter 2 following a 
toxicity profile. The study also examines different storage conditions and its effects on sample 
degradation.  
Chapters 4 and 5 examine the use of zebrafish as a model to understand lipid metabolism under 
chemical modulation and external feeding respectively. Chapter 4 “Rapid quantification of 
neutral lipids and triglycerides during zebrafish embryogenesis”. Here a novel method is 
described to quantify the deposition of neutral lipids and triglycerides using Oil-Red O staining, 
a stain that is used to visually depict the deposition of lipid droplets during embryogenesis. 
Previously being only used as a qualitative assay, this new method allows it to also be used to 
quantitatively using optical density measurements.  
 X 
 
Chapter 5 “Assessment of novel algal biomass as fish feed: Accumulation and distribution of 
omega-3 long-chain polyunsaturated fatty acid in zebrafish” looks into how this novel algal 
biomass can be used as feed to study the accumulation and synthesis of mega-3 fatty acids for 
its’ potential use in aquaculture. An increasing number of studies show the positive effects of 
eating fish in normal diet, as it contains contain protein, omega-3 fatty acids and a wide array 
of highly bioavailable micronutrients. However, the biggest challenge in today’s society is 
meeting the growing demand by following sustainable approach. Hence this chapter elucidates 
whether microalgae can be used a sustainable alternative food source due to their nutritional 
quality and potentially serve as an alternative marine feed. 
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Abstract 
 
The zebrafish is fast becoming a leading and prominent model organism used by researchers 
for developmental biology, and research in modeling human diseases in zebrafish is being 
undertaken at a fast pace.  Therapeutic areas, including oncology and cardiovascular diseases, 
have zebrafish models based on known disease mechanisms that are translatable to modes of 
action in humans. Many novel assays have been and are continuing to be developed to study 
human disease in zebrafish. Prominent methods to identify novel drug targets within the 
organism include, chemical mutagenesis, insertional mutagenesis and high throughput small 
molecule screens. Methods to validate potential drug targets include reverse and forward 
genetics, transgenesis and gene knockout. Interestingly, an emerging role of the zebrafish 
model is as a platform for toxicity screening as well as an organism to investigate lipid 
metabolism and the influence of lipids under chemical modulators.  
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Current challenges in drug discovery  
 
The identification and discovery of drugs, even with the advent of many technological 
advances remains a major challenge and severely affects the pharmaceutical industry due to 
lapses in productivity when it comes to drug discovery. For the past half century the principal 
method for drug discovery has been target orientated, with the process for compound 
identification, through to preclinical testing in animal models, taking between 10 to 15 years 
(1). Currently, the process of drug discovery is predominantly based on ground-breaking 
synthetic chemistry. The application of high throughput screening, recognizes and identifies 
small molecules that show increased specificity and efficacy against an individual molecular 
target (2, 3). Therefore, it is imperative that an appropriate target be selected. It is this step in 
the drug discovery process that tends to be the weakest link. Choosing an appropriate target in 
order to validate a drug or compound of choice may not at all have to do with the disease 
biology in humans, which is intended to be targeted. Typically a target is chosen, not because 
it is known to be the cause of the underlying disease, but because knowledge about the target 
is already available to researchers. Such reasoning stems from information related to prior work 
in the field, the alleged drug ability of the target, drugs that have previously been successful in 
the field and, the data available from distinct animal models (4).  
Frequently, the selected target will have been intensively studied in a very specific context, but 
its effect and function in other tissues and cell types may be poorly documented and understood, 
including target behaviour (under encountered stressors). As a result, a majority of compounds 
are dismissed during preclinical animal testing as they fail to meet the standards of Absorption, 
Distribution, Metabolism, and Excretion (ADME). This is a consequence of in vivo testing 
being carried out on pre-clinical animal models in later stages of drug development.  
In addition, most pre-clinical animal models are expensive or highly inbred. Furthermore, it is 
not uncommon to see unanticipated off targets or eccentric responses elicited by the drug in 
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rare genetic variants of the animal (5-7). In contrast, several drugs have been repurposed for 
diseases that were not a part of the initial drug screen for a particular disease, with these drugs 
being discovered unexpectedly and often during focusing on a completely different disease(8). 
The outcome of the drug being toxic or therapeutic in nature is due to its interactions between 
multiple targets (9, 10). Therefore, an effective drug discovery screen would not just focus on 
a single target but all feasible targets in the context of the disease.  
As medical research progresses in the modern world, there is an ever growing need to identify 
potential drug targets for human applications. Although, the emergence of computer modelling 
of disease models has brought about important improvements in drug discovery,  cell line based 
models (in vitro and ex vivo) and animal testing (in vivo) still play a crucial and pragmatic role 
in modern day drug discovery and validation. Animal studies continue to be essential when 
determining the pharmacokinetics, as well as distinguishing the effects of a drug on tissue 
remodelling. In addition, animal studies are capable of determining subsequent systemic effects 
that may be associated with the specific molecular targets. Furthermore, optimal timing for 
intervention by therapeutics can only be evaluated and measured in the appropriate animal 
model of human disease states, as it allows the development of drugs specifically targeting the 
disease of interest.  
Therefore, it is vital to evaluate drugs and compounds during early stages of development by 
utilising inexpensive whole organism vertebrates as researchers can gather insight into drug 
toxicity, bio-availability and tissue specificity which may not be accurately measured in some 
murine models to increase success in the later stages of drug development. 
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Zebrafish as a model for drug discovery  
 
The zebrafish (Danio rerio), a tropical fish that originates from the streams of Southeast Asia, 
once common in home aquariums, is now being utilized by researchers around the world in 
many diverse fields of research to study and investigate developmental and evolutionary 
biology as well as toxicology and pharmacology (11). The zebrafish is regarded as a powerful 
tool by researchers and pharmaceutical companies to aid in drug discovery by accelerating the 
drug screening process for human therapeutics. In the 1970s, the zebrafish was recognized as 
a highly useful model organism, due to its rapid organogenesis and transparency during 
embryogenesis. Later in the 1990s, the zebrafish was successfully used as the first vertebrate 
organism to undergo a high-throughput mutagenesis screen to produce produced thousands of 
mutations, all the known human disease genes, most are conserved in zebrafish (12). Zebrafish 
possess many characteristics and attributes that make them the ideal candidate in the context 
of drug discovery. Zebrafish, due to their rich and high fertility, produce large number of 
embryos, approximately 200-250 embryos per mating. Unlike mammalian embryos that are 
hidden within the uterus, zebrafish embryos develop externally after fertilisation by adult male 
zebrafish and therefore are better suited for the study of vertebrate developmental biology (11). 
In addition, the maintenance costs associated with zebrafish are considerably lower than the 
mammalian models (13). Moreover, embryogenesis occurs rapidly, with  the majority internal 
organs (heart, kidney, liver and intestine)  functional by 96 hpf (Figure 1) (13). Furthermore, 
zebrafish larvae can be manipulated to inhibit pigmentation during development. This allows 
for in vivo imaging and real time investigation of organs, cells and tissues (14, 15). In addition, 
zebrafish via temporal and spatial determination of gene expression are highly amenable to 
molecular and genetic analysis. This allows for the investigation into specific gene functions 
using Crispr/Cas gene editing, transgenesis and through large scale mutagenesis (16, 17). 
Furthermore, zebrafish can be directly exposed to the compounds of interest through the 
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aquaria water that they are housed in. Once absorbed through the skin or ingested (once the 
embryos are able to swallow), the compounds can be screened for target effects(12, 18, 19). 
The automation of fluorescent zebrafish assays allows for the screening of a large library of 
compounds providing high throughput screening of compounds (12). Finally, and most 
importantly a high degree of genetic conservation (~75%) exists between the zebrafish and 
human genomes (20). 
 
Being similar to the human development makes the zebrafish a powerful vertebrate system 
being currently used for the rapid screening of compounds in vivo. Furthermore, the key stages 
in embryogenesis such as, the stages and processes of cleavage, gastrulation, somitogenesis 
and organogenesis are similar between zebrafish and humans. A key difference that makes the 
zebrafish an appropriate model to study embryogenesis is the rapid non-placental growth of 
embryos that occurs ex vivo under the influence of maternal transcripts as compared to the 
mammalian animal models. For example, when it comes to modelling the cardiovascular 
system, similarities between the zebrafish and humans include, a multi-chamber heart both 
having an atrium and ventricle, a circulatory system/network compromising of arteries and 
veins and, a separate lymphatic circulation. However, there are a few notable differences in the 
cardiovascular system of both organisms. The zebrafish have a left and right distinction in 
cardiac anatomy as they do not have a separate left and right circulation, since the heart has 
only two chambers. Moreover, the haematopoietic and immune (includes lymphoid) systems 
development in the zebrafish and humans share many haematopoietic cell types, such as, 
erythrocytes, all myeloid cells, T and B lymphocytes, and innate and adaptive humoral and 
cellular immunity. A number of key similarities between zebrafish and humans can be observed 
including, the blood which contains nucleated erythrocytes and have thrombocytes instead of 
platelets. Key differences include, the haematopoietic site in zebrafish is in the kidney 
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interstitium, and compared to humans this process occurs in the bone marrow. The 
gastrointestinal system in the zebrafish and humans also share many of the major organs: the 
liver, exocrine and endocrine pancreas, gall bladder and immune cells in the lamina propria. 
However, zebrafish lack an acidified digestive organ and rather than a stomach, possess an 
intestinal bulb (also lack an intestinal Paneth cell). Due to the similarities in the cardiovascular, 
nervous and digestive system between the zebrafish and humans, zebrafish can be utilized as a 
platform to identify novel disease associated targets, conduct large scale mutagenesis (12), and 
aid the high-throughput identification of the targets of interest using genetic and chemical 
screens. 
The zebrafish genetic screens follow one of the two main methodologies; either a forward or 
reverse genetics screen (Figure 2) (21). Forward genetics is what is better known as ‘phenotype 
to genotype’ screen, centred on the identification and characterization of specific phenotypes, 
which is then used to identify the underlying genetic mutation. The zebrafish platform has 
emerged as a powerful tool in the identification of developmental phenotypes caused by 
chemical mutagenesis, N-ethyl N-nitrosourea (ENU) and insertional mutagenesis (virus or 
retrotransposon mediated). This has allowed the identification of many genetic mutations, such 
as those identified in cancer, cardiovascular disease and diabetes (16, 17, 22-24). In contrast, 
reverse genetics is based on the principle of ‘genotype to phenotype’ screen, where a gene of 
interest is chosen and targeted by genome editing to uncover the phenotype. Reverse genetics 
can be achieved by either utilising the Crispr/Cas system, Targeting Induced Local Lesions IN 
Genomes (TILLING) or by zinc finger nucleases, in order to uncover the function of the genetic 
mutation within the zebrafish (25-30).  
Morpholinos (MOs) played an important role in the field of reverse genetics screens, however 
recently concerns have been put forth in regards to MOs and the specificity of their effects. 
Indeed it has been demonstrated that reverse genetic screening revealed a poor correlation 
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between MO induced and mutant phenotypes in the zebrafish, with a small proportion of genes 
causing adverse defects during embryogenesis, and the phenotypes not correlating with 
previously published MO induced phenotypes (morphants) (31). Furthermore, it was revealed 
that approximately 80% of the published morphants defects/phenotypes with the Sanger 
Zebrafish Mutation Project were not observed in the mutant embryos. Hence, it was suggested 
that the mutant phenotypes in zebrafish may become the gold standard to define gene function 
(31). 
However, it has been argued that the use of MOs in organisms with poor experimental genetics 
has been beneficial. This has been demonstrated through the usefulness of MOs in analysing 
and understanding the development of sea anemone (32). In human trials, MOs also proved to 
be useful in inducing exon skipping in Duchenne muscular dystrophy (33). Furthermore, MOs 
can be utilised to achieve graded knockdown of gene function by titrating MOs to elicit dose-
dependent effects to analyse graded phenotypes to reveal subtle or transitional defects, which 
may be missed in the complete loss of function mutants. The ability to titrate MOs and use 
them in a dose-dependent capacity, allows researchers to achieve tunable gene inactivation 
which is usually difficult to achieve genetically. Therefore, it is arguable that MOs where 
applicable should be used in combination with other genetic modification tools such as Crispr, 
as they believe that achieving the same outcome using more than one technique is more 
beneficial for science than any one approach (34).  
Chemical genetics screens in many ways are parallel to and complement the traditional genetic 
methods (21). First, small molecule compound libraries are available in which the biological 
function of these compounds is known, which allows for the rapid interpretation of consequent 
biological pathways within the zebrafish (Figure 3). In addition, zebrafish can be treated with 
the chemical/compound under investigation at any point during embryogenesis. This permits 
the elucidation of the latent effects of genes during development. Furthermore, when 
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investigating the tissue specificity or the essential functions elicited by the chemical/compound 
in question, the dosage delivered to the organism can be controlled. Small molecule screens 
permit for the identification of relevant targets, whilst adhering to the physiological context of 
the organism. This gives preference towards compounds that are more likely to be cell 
permeable, present low levels of toxicity, and have an effective pharmacokinetic and 
pharmacodynamic profile (35). These properties make them effective candidates during drug 
development. As seen in genetic screens, both forward and reverse genetic approaches for 
compound validation can be achieved by chemical genetic screens (21, 35). Forward chemical 
genetics is based on the phenotype based small molecule discovery, where libraries comprising 
inhibitors can be screened for a specific phenotype further leading to the identification of drug 
target(s) based on the observed phenotype. Likewise, reverse chemical screening involves the 
testing of chemical inhibitors with already known molecular targets in order to unravel specific 
phenotypes in zebrafish. Using the zebrafish platform, reverse chemical screening can aid in 
the identification and optimization of novel bioactive compounds (35). 
The ability of zebrafish to be used in a multitude of genetic screens, make them an excellent 
platform to examine gene function, high volume compound screening, target identification and 
validations, assay development and drug toxicity studies. Ultimately, zebrafish has become the 
model organism chosen by many researches to elucidate the role of drugs in disease models 
which is represented by the evident increase in zebrafish publication in recent years. 
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Drug discovery and validation in Cancer 
 
As an in vivo model zebrafish offer immense potential into the investigation of the molecular 
mechanisms underlying the aetiology and progression of a vast array of human diseases (21, 
36-43). In particular, zebrafish harbour a genetic background, which has been fully sequenced. 
In addition, zebrafish possess immune, vascular, hematopoietic, and musculoskeletal and 
nervous systems that are similar to humans. Organs and tissues in a zebrafish; such as the heart, 
eyes, ear, gastrointestinal tract, pancreas, liver and kidney are similar in phenotypic 
resemblance/structure to that of humans (36, 41, 42, 44-49). Studies in zebrafish involving 
mutagenesis combined large-scale screens, have generated many mutant fish displaying 
particular phenotypic features and tendencies. These have been linked or associated with a 
predisposition to the development of certain cancers that may potentially be exploited as 
models for human disorders that definitively establish the function of certain gene products and 
drug targets (50-53). Numerous transgenic zebrafish models have been created that present and 
mature with neoplasms with comparable histology, morphology and cellular alterations to 
human cancers (41, 42, 44, 46-49). Therefore, the molecular mechanisms and functions of 
particular gene products that influence the progression of various cancers, as well as the 
accompanying resistance to treatments, have been by the use of transgenic and mutant zebrafish 
models (40-42, 45, 46, 48, 54, 55). These cancers consist of but are not limited to germ cell 
tumours, lymphomas, melanomas, embryonic rhabdomyo-sarcomas (ERMS), and a variety of 
epithelial cancers including, liver, gastrointestinal, colon, pancreatic, prostate and breast 
cancers (40-42, 45, 46, 48, 54-56). The zebrafish embryos are as proliferative as cell culture 
systems and therefore, are comparable to being as applicable as in vitro systems for the study 
of cancer progression and development.  
The two major classical approaches used for cancer models: (1), xenografts of cancer cells 
from other organisms or allografts from zebrafish donors with cancer; and (2), construction of 
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zebrafish cancer mutant lines or transgenic oncogene lines (57) (Table 1) make zebrafish an 
outstanding model in the discovery and validation of anti-cancer drugs. 
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Zebrafish Cancer Models  Chemical/genetic 
alterations 
Type of Cancer/Tumour induced Reference 
Chemical Treatment DMBA Hepatocellular carcinoma, cholangiocarcinoma, intestinal cancer, 
Germ cell tumour, Testis, Vascular 
(58, 59) 
NDMA Hepatocellular carcinoma, cholangiocarcinoma (60, 61) 
MNNG Liver, intestinal  (62, 63) 
ENU Liver, testicular cancer (64) 
DEN Testicular germ cell tumour  (61, 65) 
Transgenesis TEL-AML1 B-All (49) 
MYC T-All (66) 
NOTCH1 T-ALL (67) 
MYCN Neuroendocrine Tumour, Neuroblastoma, MPN (68-70) 
BRAF-V600E Melanoma (42) 
Knockout P53 Malignant peripheral nerve sheath tumors (71) 
APC Colon adenoma (72) 
pten T-cell acute lymphoblastic leukemia and hemangiosarcoma (66, 73) 
NF1 Gliomas and malignant peripheral nerve sheath tumors (74) 
GSTTI Lymphoma (75) 
Overexpression Akt1 Lipoma (76) 
KRAS(G12D) Rhabdomyosarcoma (77) 
MYCN and fgf8 Neuroblastoma (78) 
NRAS, BRAF in p53 Melanoma (71, 79) 
Myc T-cell leukemia and hepatocellular carcinoma (45, 80) 
Myc, Xmrk and KRAS(V12) Hepatocellular carcinoma (80) 
Xenotransplantation Transplant tumour cells 
into zebrafish 
Melanoma, glioma, hepatocellular carcinoma, lung cancer, 
pancreatic cancer, ovarian carcinomas, breast cancer, prostate 
cancer, retinoblastoma, leukemia 
(81-90) 
Table 1: Various cancer modelling in zebrafish 
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The principle advantage in using the zebrafish to model cancer is the ability to use them as a 
xenotransplantation platform. In zebrafish, the innate immune system is active and detectable 
by 1 dpf, on the other hand the mature adaptive immune response is fully functional between 
4 to 6 weeks after fertilization when the lymphocytes become functional (91-95), which makes 
the zebrafish an ideal candidate for xenotransplantation of human cells without the risk of 
rejections (21, 37, 39, 61, 96-100). Therefore, human cancer cell lines, purified subpopulations 
of cancer cells or primary patient cells can be directly injected into zebrafish embryos to study 
different aspects of tumour biology (101, 102). Zebrafish models only necessitate a few cancer 
cells, which include cancer stem and progenitor cells with stem cell-like properties in order to 
rapidly define tumorigenic and metastatic properties. Several types of human cancer cell lines 
and primary patient samples, have been successfully transplanted into 48 hpf zebrafish 
embryos, including gastrointestinal, neuroendocrine, leukemic, and melanoma clinical tumour 
samples. This demonstrates the important role zebrafish play in studying cancer pathogenesis, 
role in novel drug screening and the therapeutic testing of candidate cancer drugs (103). A 
xenotransplantation platform in the zebrafish model presents numerous benefits compared to 
the more convectional murine models. Conventionally, the animal model used for investigating 
human cancers is the murine model, but the principle drawback in using rodents to model 
xenotransplantation is that mice and rats used are immunocompromised, and do not represent 
the behaviour exhibited from naturally occurring cancers in humans accurately (104, 105).  
Anti-neoplastic drugs and their effects have repeatedly been discovered and identified via 
biochemical assays or within cell line models (106, 107). However, due to a lack of biological 
context in terms of what will transpire in vertebrate models, the outcomes of the screening 
process are often unsatisfactory. Thus, the active compounds that were discovered during the 
screening process were ineffective when translated in a vertebrate model. This is where a whole 
organism like the zebrafish provides invaluable insight into anti-neoplastic drugs on, organ 
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toxicity, anti-tumour effects, pharmacokinetic data and drug interaction centred on a whole 
organism platform (108). Unlike the mouse model which limits large scale screening simply 
due to expense, and animal numbers, zebrafish can be utilised in high-throughput antineoplastic 
drug screens due to the high production of embryos. Moreover, the larvae are of small size 
and/can be arrayed in a 96 well plate for large screen drug screens, significantly decreasing 
laboratory costs (109). Furthermore, most cancers can be modelled in zebrafish and therefore, 
the model can be used to evaluate the chemotherapeutic drugs for their anti-tumour effects, and 
monitor the growth of tumour cells and its grade (level of invasion).  
Due to the relatively larger size of the adult zebrafish and full pigmentation compared to an 
embryo, they possess little aid in drug screening. However, in recent years the opacity of the 
adult zebrafish has been greatly improved due to the introduction of the Casper zebrafish 
(Figure 4), a transparent adult zebrafish. This mutant has provided the ability to explore the 
underlying mechanisms behind tumour dissemination and subsequently metastatic growth 
throughout the fish development, well beyond the zebrafish embryonic stages (110). Casper 
zebrafish are double mutants for nacre and roy (Casper; roy-/-, nacre-/-) (110). 
Characteristically, the adult zebrafish pigmentation is influenced by three distinct classes of 
pigment cells, black melanophores, reflective iridophores and yellow xanthophores (111). 
Nacre mutants completely lack melanocytes due to a mutation in the mitfa gene (112), whilst 
the roy zebrafish lack iridophores completely (110).  
Tumour dissemination throughout zebrafish occurs at varying rates, usually from 5 to 10 days 
post transplantation. Consequently, the appearance of disseminated tumour cells may not occur 
until 2-3 weeks post transplantation (110, 113). Hence, the use of the Casper fish in tumour 
cell transplantation platforms will be immensely valuable in monitoring in vivo tumour 
engraftment and migration following transplantation. Zebrafish xenograft models of human 
cancer are particularly valuable in drug screens as they allow for simultaneous examination of 
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in vivo efficacy and toxicity of candidate drugs. Therefore, it will be paramount in assessing 
the effects of anti-cancer drug treatments in adult zebrafish that have been transplanted with 
human cancer cells. 
Drug validation and embryo screens in an adult zebrafish model of cancer signify the perfect 
method to ascertain and highlight optimal candidate agents and/or drugs for further testing in 
mammalian models. As a result, researchers have benefited from modelling cancer in zebrafish 
as they have successfully identified and tested candidate drugs/compound of the treatment of 
cancer.  
Increased chemical screens have been conducted in zebrafish, with anti-melanoma chemical 
genetic screening one of these. Approximately 2000 chemicals were screened to establish 
inhibitors of the neural crest lineage in zebrafish embryos. The progression of melanoma is 
unfavourably linked to the neural crest lineage; hence the selected chemicals/compounds were 
tested for their effects in melanoma. A compound identified to inhibit the progression and 
propagation of both neural crest and human melanoma was identified to be an inhibitor or di-
hydrooroate dehydrogenase (DHODH) called Leflunomide. The inhibition of DHODH through 
Leflunomide successfully suppressed melanoma growth/progression in murine models, hence 
this screen validated the role of zebrafish in anti-cancer drug discovery (114).  
Furthermore, haematopoietic system development is highly conserved between humans and 
zebrafish. Most human adult blood lineages have equivalent homologous cell lines in zebrafish 
(115). Hence, it may be hypothesised that successful hematopoietic drugs (in the context of 
anticancer therapeutics) in zebrafish could serve the same function in humans. In 2012, an anti-
leukaemia compound screen was conducted in zebrafish leading to the identification of more 
than 25,000 small compounds. In the subsequent drug screen, a compound called Lenaldekar 
(LDK) was identified that induces long term remission in zebrafish with T-cell acute 
lymphoblastic leukaemia (T-ALL). In a successive study, LDK had a widespread anti-
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leukaemia effect targeting T-ALL, as well as B-cell acute lymphoblastic leukaemia (B-ALL) 
and Chronic Myeloid Leukaemia (CML) (116, 117). Notably, the LDK dose that was found to 
be successful in zebrafish was tolerated and effective in a murine models (117). 
Subsequent screening of 288 new anti-angiogenesis compounds identified two kinase 
inhibitors with anti-angiogenic properties and a phosphorylase kinase subunit G1 (PhKG1) 
confirmed as the kinase target (118). Comparably, Rosuvastatin was identified to play a role in 
angiogenesis inhibition in the developing zebrafish embryo (119). In addition, anti-lymphatic 
drug compounds were also recognized in zebrafish, with four compounds, that were formerly 
used in humans and exhibited anti-lymphatic activity in zebrafish (120). 
Due to the rapid development of the zebrafish, antineoplastic drug/compound toxicity can be 
detected over a short period of time. A screen for detecting the toxicity of anti-tumour drugs 
by assessing the inner ear hair cell toxicity revealed that 13 out of the 88 tested anti-tumour 
drugs exhibit genuine ototoxicity. Parameters including cell damage, vitality and normal 
development are investigated/ studied to assess the toxicity of anti-neoplastic drugs. The 
screening for drug toxicity is vital in assessing a suitable therapy in the treatment of clinical 
cancer (121). 
In the aspect of clinical drug discovery, the optimal model for drug discovery would be a 
mammalian platform, with the prime candidate belonging to the murine family, such as mice 
or rats. However, researchers often face problems when using a murine platform for cancer 
research. The most common being, it is extremely difficult to perform real-time imaging of 
minute tumour lesions in deep tissue. Hence, it proves cumbersome to monitor the real time 
effects of an anti-tumour drug (122). Drug efficacy can therefore, only be evaluated post 
autopsy. In zebrafish models, real time non-invasive effects of an anti-tumour drug can be 
evaluated and imaged whilst the organism is alive. As pigmentation can be inhibited during 
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embryogenesis allowing for relatively easy tracking and imaging of the embryos. Furthermore, 
the substantially high cost of a murine platform dismisses the use of the platform for high 
throughput screen of drug discoveries. This ultimately demonstrates that zebrafish, as a model 
for cancer provides an effective platform for large-scale antineoplastic drug screens including 
drug efficacy detection.  
Drugs discovered using the zebrafish model have been put into clinical trials, passing phase 1 
trails. Indeed it was shown that prostaglandin E2 (PGE2) exposure either ex vivo or in vivo 
increased engraftment of Haematopoietic stem cell (HSC) transplantation. PGE2 was 
discovered from a screen of 2500 chemicals to assess the effects on blood stem cell production 
(123). PGE2 can be used as an effective treatment for lymphoma, leukaemia, blood disorders 
and a myriad of other auto-immune disorders (124). Successful transplantation of HSCs is 
dependent on efficient homing and engraftment of HSCs and regulation of haematopoietic 
development by PFE2 (124). A chemical derivative of PGE2 is being developed by Fate 
Therapeutics under the name Pro Hema®, and is based on the work done by Zon et al., to 
improve the success of HSC transplants using umbilical cord blood.  
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Drug discovery and validation in Cardiovascular Diseases 
 
Zebrafish heart is the first organ to develop during embryogenesis and acquires full 
functionality by 2 dpf (125). In comparison, heart develops by 12 dpf in mouse models and 35 
dpf in the human embryo (126). The heart in a zebrafish embryo consists of 2 chambers and 
resembles the heart of a human embryo at 3 weeks of gestation (125). Even though the zebrafish 
heart is 2 chambered and lacks pulmonary circulation, there is substantial conservation and 
homology between the zebrafish and mammalian cardiovascular development at the genetic, 
physiological and morphological level. Early haematopoietic and vascular development in 
zebrafish is highly similar to mammalian development (127). This makes the zebrafish a useful 
model of studying cardiac development and a valid model and platform for drug discovery; 
pertaining to cardiovascular diseases, table 2 outlines some of the zebrafish mutants that are 
used to study cardiac defects. 
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Zebrafish Mutant Gene Associated Cardiac Phenotypes References 
Gridlock hairy/enhancer of split-related 
(hey2) 
absent blood circulation to the tail; comparable with human 
coaction of the aorta 
(128, 129) 
Breakdance kcnh2 2:1 rhythm (loss-of-function) (130-132) 
Reggae kcnh2 Intermittent cardiac arrest (overactivation) (133) 
Santa CCM 1 Loss of concentric growth of ventricle; absence of AV 
conduction delay 
(134, 135) 
Valentine CCM2 Loss of concentric growth of ventricle; absence of AV 
conduction delay 
(134, 135) 
Hobgoblin tcf2 AV block (134) 
Dead beat phospholipase Cγ1 Deterioration ventricular contractility; lacks lumenized 
vasculature 
(136) 
Silent heart cardiac troponin T Non-contractile heart; disorganized sarcomeres (136) 
Slipjig foxn4 Failure to loop; lacks AV conduction delay (137) 
Pickwick titin Poor contractility; disrupted sarcomeres (138) 
Table 2: Select zebrafish mutants and their resulting phenotypes 
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To take full advantage of drug target validation, appropriate assays are essential to determine 
whether knockdown of the target gene affects a disease-related process. As a result it is possible 
to examine the effect of diminishing the function of a specific gene on newly forming blood 
vessels in the zebrafish embryo. This will allow for the investigation into whether a blood 
vessel specific gene is a valid target for anti-angiogenesis drugs. The formation of blood vessels 
is needed for embryonic development and function and plays a vital role in the pathogenesis of 
a myriad of chronic human diseases.(139-141). A well characterized and understood 
therapeutic target is angiogenesis and numerous assays are available and used for anti-
angiogenic drug screening (142). Models targeting endothelial cell migration, apoptosis, 
proliferation and tube formation are simple and highly throughput, and widely used. However, 
a major disadvantage of these assays is that they fall short compared to their in vivo system 
counterparts due to the lack in biological complexity. Assays such as the corneal 
neovascularization assay, chick chorioallantoic membrane assay and the Matrigel plug assay 
retain the biological complexity that is desired but are low throughput and rather costly (143).  
Transgenic zebrafish in recent years have revolutionized the field of drug discovery and target 
validation. Transgenesis has allowed for the in vivo observation of particular cellular processes 
and cells with relative ease. It functions on the principle that a fluorescent protein is expressed 
under the control of a promoter and this results in a tissue specific expression where the 
promoter is activated (Figure 5) (144-146). In turn it can be utilized to parallel cellular 
morphology and/or gene expression before and after drug exposure (144). A major advantage 
of transgenic zebrafish lines is the stability of the incorporated transgene across multiple 
generations. Transgenic lines routinely used for cardiovascular disease research such as; Flk1: 
GFPnls transgenics express green fluorescent protein (GFP) localized to the nucleus of 
endothelial cells (147) and Fli1: eGFP expresses GFP throughout endothelial cells which in 
turn facilitates imagine of the vascular anatomy (145). In addition, the GATA1: dsRed line 
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expresses fluorescence in erythrocytes and this enables the visualisation and quantification of 
blood flow (127). 
Tran et al., used transgenic zebrafish expressing green reef coral fluorescent protein (GRCFP) 
to screen the LOPAC1280 compound library for anti-angiogenic compounds. The transgenic 
zebrafish expressing GRCFP under the control of the vascular endothelial growth factor 
receptor (VEGFR) 2 promoter [TG(VEGFR2:GRCFP)] allows visualisation of the blood 
vessel-restricted expression in the screening assay;  an automated assay for anti-angiogenic 
compound identification using transgenic zebrafish embryos for the discovery of anti-
angiogenic compounds. SU4312 and AG1478, two known anti-angiogenic compounds were 
identified as hits, as well as indirubin-3’-monoxime (IRO), a compound with no previously 
known anti-angiogenic activity. IRO functions by inhibiting human umbilical vein endothelial 
cell tube formation and proliferation. Therefore, this for the first time, demonstrates and 
highlights the first anti-angiogenic compound validated in a zebrafish assay that also has 
palpable and validated activity in human endothelial cell based angiogenesis assays (143). 
As previously mentioned hundreds of mutant zebrafish lines have been created via large scale 
mutagenesis screens (127) and express mutant phenotypes that resemble human cardiovascular 
disorders (148, 149). Large scale small molecule screen using the zebrafish model has become 
an established and trusted platform for the identification of biological effects of novel 
compounds (150). Previously, this has been limited to and only performed in cell culture 
systems or in organisms such as yeast and Drosophila organisms that are considered 
evolutionarily distant from humans (151, 152). Due to its advantages in drug discovery and 
target validation the zebrafish has emerged as a candidate for high-throughput small molecule 
screening (153).  
The gridlock mutation, a vascular defect was established in zebrafish where, the paired lateral 
dorsal aorta is unable to fuse and results in the formation of a single dorsal aorta in the anterior 
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trunk. This leads to absent blood circulation to the tail and is comparable with human coaction 
of the aorta (126, 127). The gene responsible for the gridlock phenotype is a hairy/enhancer of 
split-related (hey2) transcriptional repressor implicated in a signalling pathway controlling 
vascular cell fate decisions (128, 129). Following the screening of 5000 small molecules, two 
classes of compounds were discovered that could supress the phenotypic effects of the gridlock 
mutation and therefore, completely restore normal circulation in mutant animals (128, 154). 
Subsequent experiments demonstrated that the compounds functioned by triggering the VEGF 
(vascular endothelial growth factor) pathways. The experiments also identified opposing 
actions of the ERK (p42/44 MAP kinase) and PI3K (phosphatidylinositol-3-kinase) signalling 
in the venous/arterial cell fate decision (154). This detection was a prime example of how 
phenotype based screening in vivo resulted in the discovery of novel molecules that can activate 
the VEGF pathway, as well as novel relations between PI3K and arteriogenesis. The gridlock 
supressing compounds encompass a novel class of compounds that previously were not known 
to influence vasculogenesis or angiogenesis. In addition, microcytic hypochromic anaemia is 
easily replicated in zebrafish with the sau mutation caused by the delayed erythroid maturation 
and abnormal globin (127). Genes that are investigated for drug target validation when 
assessing the effects on anaemia and thrombosis include, Factor VII, COX-1 and COX 2 (155, 
156).   
In a study conducted by Milan et al., 100 small molecules were screened to assess their effect 
on the zebrafish heart rate (157). This revealed the majority of drugs that result in QT interval 
(time between start of ventricular contraction and ventricular repolarization) prolongation in 
humans trigger AV (atrioventricular) block or bradycardia in the zebrafish, thus validating the 
zebrafish model as a suitable tool for preclinical drug screening/testing for cardiac conduction 
and pro-arrhythmia (157). In a follow up study by Milan and colleagues, early steps involved 
in the patterning of the conduction system were identified and revealed the formation of a ring 
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of AV conduction tissue at 40 hpf in the zebrafish heart (158). It was further revealed that both 
the protein and the gene neuregulin and notch1b are essential for the formation of AV 
conduction tissue (158). 
 
The optical transparency of zebrafish during embryogenesis allows the intricate visual mapping 
to define the cardiac conduction system (CCS). Chi and colleagues were able to define and 
identify 4 distinct CCS developmental stages using the cmlc2: gCaMP transgenic zebrafish 
line expressing a cardiac specific fluorescent calcium indicator (134). Subsequently, they set 
out to identify the key regulators of CCS development with the aid of an ENU mutagenesis 
screen. Seventeen conduction specific mutations were identified, which included the 
homeobox transcription factor gene tcf2 (134). In addition to notch and neuregulin identified 
by Milan and colleagues, numerous novel genes involved in the regulation of AV conduction 
were identified as potential therapeutic targets for cardiac conduction disease (158).  
 
In the same way, type 2 long QT syndrome which is a result of genetic defect/mutation in the 
KCNH2 gene has been modelled in the zebrafish. The mutation leads to a prolonged cardiac 
repolarization and ultimately life threatening arrhythmias. The KCNH2 mutant in the zebrafish, 
breakdance, manifest with prolonged ventricular action potential duration, impulsive early 
after depolarisations and two atrial contractions for each ventricular contraction (2:1 AV block) 
similar to the human diseased state. These effects are easy to observe during zebrafish 
embryogenesis (159). Flurandernolide and 2-methoxy-N-(4-methylpehnyl) benzamide (2-
MMB) were recognized as being suppressors of the long QT phonotype, from a chemical 
screen of around 1200 small molecules (160). The voltage sensitive dyes, Flurandernolide and 
2-MMB were further established to shorten ventricular action potential via optical imaging 
(160). Consequently, zebrafish models provide an in depth evaluation and modulation of the 
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electrophysiological properties of the heart, with the principle objective of ascertaining and 
identifying putative therapies for human arrhythmias and cardiovascular disease on a broader 
horizon.  
Extensive in vivo chemical screening utilising zebrafish have identified compounds for their 
therapeutic potential in improving chord or marrow transplants. Compounds have been 
discovered that will mobilise iron from intracellular stores, with the potential use in treating 
anaemia (123, 161).  Yu et al., successfully discovered an inhibitor of bone morphogenetic 
protein (BMP) signalling, following a screen of over 7500 compound (161). For the study of 
human cardiovascular disease, zebrafish has emerged as a valuable model and presents a 
myriad of opportunities for high throughput chemical screening to interpret biology as well as 
to identify small molecules that are involved in modulating disease associated pathways. 
Furthermore, the zebrafish possess a unique ability to regenerate cardiomyocytes (162), hence 
providing a platform to develop therapies targeting advanced heart failure. Moreover, with the 
ease of genome editing within the zebrafish embryo, novel mutagenesis techniques such as 
Crispr/Cas (163) can be used in aiding drug/compound target validation. It is no doubt that 
future investigations and studies will take advantage of the zebrafish model to correlate and 
pair human genetic mutations with their molecular functions. In addition, enhanced and 
developed screening techniques will facilitate high throughput investigation in zebrafish, 
which will aid in the discovery of novel drugs and therapies to fight cardiovascular disease. 
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Zebrafish – A suitable model for in vivo toxicity testing  
 
The average cost of research and development for each new drug has been estimated to be 
greater than $US 800 million, partly owing to the high rate of compound failure in clinical 
trials. An important strategy for lowering drug development costs involves termination of 
compounds as early in the process as possible, before substantial resources have been invested 
in clinical trials (164, 165). Although improvements in pharmacokinetics/ADME profiling 
have reduced failures in clinical trials (166, 167), toxicity continues to be a major factor in the 
attrition of candidate drugs. Recent reviews indicate that anywhere from 20 to 50% of failures 
can be attributed to toxicity and clinical safety (167-169).  
However, the Food and Drugs Administration (FDA) believes that technological difficulties in 
assessing toxicology as one of the chief perpetrators in facilitating this problem. The FDA 
reports improvements in predicting failures before clinical trial by even 10% would save the 
United States $100 million per drug in development costs (170-172). However, in order to 
evaluate toxicity of drugs in trial and to involve toxicology earlier in the drug discovery 
processes, a developed and more suitable animal model platform is vital. The Environmental 
Protection Agency (EPA) has proposed toxicity testing strategies, which can often be described 
by three testing approaches: battery, tiered, or tailored (173). Simply, battery testing applies a 
specific set of toxicity tests to all chemical in a group, tiered testing, results from toxicity tests 
guide the nature and extent for further testing, and tailored testing uses information such as: 
exposure, potential adverse effects and mechanisms of action to determine what tests must be 
done (173).  
In order to elucidate the toxicity of any given drug and their mode of action, it is important to 
know the endpoints of toxicity elicited as well as the dose response relationships. This will 
provide vital information needed to determine the toxicodynamics of the drug. Even though 
mammalian toxicity studies remain the benchmark for prediction of risk in humans, they are 
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generally expensive, time consuming and require large amounts of test compounds. These traits 
alone make them a poor candidate for early stage toxicology screening. Due to this, they are 
generally utilized in latter parts of the drug discovery processes and are not involved in the lead 
optimization stages.  
In addition, drug developers are under constant pressure to decrease the numbers of vertebrate 
animals used for the purpose of toxicity testing (174). Hence, in vitro molecular models have 
been developed and evaluated for their use in predictive toxicity signatures. These models will 
facilitate in the evaluation of transcriptional profiling, including a myriad of ‘omics’ (168, 175). 
In vitro assays, are therefore, very useful in high throughput screening, however have been 
severely disadvantaged by the difficulty of correlating associated transcriptional profiles with 
known mechanisms of toxicity (176). Furthermore, when it comes to mimicking the 
metabolism of a whole animal to reliably model multi cellular processes, cell based assays are 
often limited (177, 178). The supposed advantage with using systems toxicology, based on 
integrations with omics data and traditional toxicity end points is to increase the predictive 
outcome. However, this method is yet to be completely validated when it comes to early stage 
drug discovery, and may not be time and cost effective (178).  
As a result of the limitations presented from both the traditional mammalian models and in 
vitro approaches, there has been increased interest shown towards zebrafish based assays to 
measure safety and toxicological end point. The zebrafish is rapidly gaining acceptance as a 
likely candidate for the screening of drug and chemical toxicology (179, 180). Using the 
zebrafish whole libraries consisting of a large number of compounds can be assessed efficiently 
for toxicity. Zebrafish assays have been developed to investigate and assess toxicities during 
drug development. A susceptible zebrafish assay was carried out for detecting small molecule 
induced mutagenesis, zebrafish embryos were also used to compare the developmental toxicity 
resulting from ethanol or acetaldehyde exposure (181, 182). In addition using zebrafish the 
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toxicity of the anti-rheumatic drug, diclofenac was evaluated (183), as well as, recently toxicity 
exhibited by novel organoiridium (III) complexes was assessed in vivo using the zebrafish, in 
the hopes for a potential treatment for prostate cancer (184). 
Indeed the use of zebrafish during embryogenesis to screen the ToxCast™ Phase 1 chemical 
library has been investigated. Toxicity incidence and potency was associated to chemical class 
and hydrophobicity (logP) (185), with chemicals/compounds with higher logP values more 
toxic to developing zebrafish embryo, and vice-versa with low logP values. They aimed to 
further elucidate a range of logP values in order to extrapolate zebrafish doses with mammalian 
doses.  
These studies show how valuable the zebrafish platform is to perform toxicity studies as 
zebrafish assays can achieve the scale and throughput of in vitro assays. However, unlike in 
vitro models, they perform in a more physiologically relevant setting where multifaceted 
pharmacodynamics and pharmacokinetic processes remain intact (21). 
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Zebrafish – A suitable model to study chemical modulation of lipids and obesity 
 
Obesity is characterised as the accumulation of adipose tissue to a level of excess such that it 
has negative effects on health (186). In the United States of America, in excess of 30% of the 
population are obese and this is the case with a quarter of men and women in many European 
countries (187). In Australia 2 in 3 adults are either overweight or obese; 10% more than in 
1995 and 15% more people living in outer regional and remote areas are overweight or obese 
than people living in major cities. Furthermore, 1 in 4 Australian children are overweight or 
obese and obesity is only beaten by smoking and drinking as a contributor to burden of disease 
(188). The World Health Organization considers a person obese when their body mass index 
(BMI) is greater or equal to 30 and they’re overweight when their BMI is larger than 25 (189). 
Accumulation of adipose tissue and subsequent weight gain occur when energy consumption 
exceeds energy expenditure over a prolonged period of time (190). The excess energy is stored 
as fat in adipocytes (fat cells), which make up a large portion of adipose tissue. Adipose tissue 
can accumulate both through hypertrophy, an increase in cell size, and hyperplasia, an increase 
in number of adipocytes (191). 
Recent studies have shown that there is substantial molecular and physiological homology 
between fish and mammalian adipocytes (192-195). It has also been shown that many of the 
same enzymes between fish and mammals are involved in lipid mobilisation and deposition 
(145). Similarly, fish adipocytes express genes homologous to mammalian adipocyte markers 
and are responsive to the same endocrine signals (192-194). 
In zebrafish the hypothalamic circuitry, which regulates energy balance invertebrates, is largely 
conserved between humans and zebrafish (196). Characteristics of models that correlate with 
obesity in humans include; hyperplastic adipocytes, ectopic fat deposition in other organs, 
blood glucose intolerance, induction of an inflammatory response, increased linear growth, 
adipocyte hypertrophy, increased plasma triglyceride levels, hepatic steatosis, and similar 
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changes in gene expression to mammalian obesity (196). Moreover, metabolic control and 
regulation of whole-body energy homeostasis involve a complex interplay between multiple 
organs and endocrine signals to carefully balance energy intake, utilisation and storage. In vitro 
studies cannot recreate the complexity that exists in vivo, so whole-animal approaches are 
required to study metabolism as it plays out in a multicellular context. Zebrafish are a good 
model in which to study metabolism because they possess all the key organs required for 
metabolic control in humans, from the appetite circuits that are present in the hypothalamus, 
through to the pancreas and insulin-sensitive tissues [liver, muscle and white adipose tissue 
(WAT)] (196). 
Furthermore, in zebrafish, similar to mammals, excess nutrients are stored in the form of large 
unilocular lipid droplets in white adipocytes, suggesting that the zebrafish could serve as a 
useful model in which to study the biology of the adipose depot itself (190). This is in difference 
to Drosophila and Caenorhabditis elegans, where fat is stored in non-specialized cells within 
the fat body or the intestine, respectively, that carry out several other functions in addition to 
lipid storage (190). In zebrafish, the first adipocytes appear in association with the pancreas at 
approximately 12 days post-fertilisation (dpf). Pancreatic WAT appearance and quantity 
correlates with fish length rather than age (196), and adipocytes and lipid droplets can by 
visualised and quantified by staining with the neutral dye Oil Red O or with Nile red, a 
lipophilic stain that fluoresces in lipid-rich environments (193). The advantage of fluorescent 
staining is that it can be used in live fish, allowing real-time imaging of the formation of 
adipocytes and their expansion under conditions of nutrient excess.  
In addition, it has been previously shown that the zebrafish can be used to study lipidomic 
composition using liquid chromatography (LC)-mass spectrometry. This study provided a 
foundation for studying lipid biology during normal or pharmacologically compromised 
embryogenesis (197). The zebrafish is considered a lecithotrophic organism (198), meaning it 
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relies on the contents of its yolk for nutrition during development until an early larval stage (~5 
dpf), after which it commences feeding. Due to this zebrafish can be considered a “closed 
system”, meaning their nutrient intake is not influenced by and external factors. As a result, 
potential experimental variables due to feeding can be eliminated during embryogenesis. This 
makes the zebrafish amenable to a variety of techniques for studying metabolism during 
development including pharmacological inhibition of key proteins involved in lipid biology 
(199, 200).  
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Conclusion  
 
Zebrafish function as an appropriate in vivo platform to complement the mammalian system as 
they share genetic similarities to humans. During embryogenesis zebrafish serve as a starting 
point for lead compound identification. Whereas for drug validation, adult zebrafish allow for 
the longitudinal observation of a compound’s impact on its target disease in a relevant model. 
The main benefit of zebrafish models is that they allow for the evaluation of ADME and 
toxicology properties of chemical compounds. They perform more efficiently, can be 
performed at a larger scale and reduce costs when compared to the more conventional murine 
models. Having been only applied in small scale molecules screens, zebrafish have now 
demonstrated their great potential in drug screens and novel compound identification for 
numerous human diseases, including but not limited to those that are discussed in this review.  
As zebrafish become increasingly utilised and applied for high throughput screens, it is 
important to remember that the anatomical and molecular differences between zebrafish and 
humans may potentially result in a set of the hits identified and generated to be eliminated. 
Therefore the relevance of the compounds identified via zebrafish screens must be investigated 
thoroughly to see if they are relevant to the human disease they are targeting. As a consequence 
the predictive toxicity assessed in zebrafish may not necessarily equate to the toxicity imparted 
in humans. This high degree of conservation that is observed between the zebrafish model and 
humans strongly highlights how valuable zebrafish are as an important platform in 
understanding the underlying mechanisms of many human diseases and disorders, and hence 
therefore will aid in the development and discovery of novel drugs. 
Furthermore, due to their developmental benefits zebrafish play a crucial and important part in 
elucidating the role of lipids in providing energy and structural cellular components during 
vertebrate development, under normal or pharmacological influence. Hence, they have been 
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proven to be a great model to understand lipid biology under chemical modulation during 
embryogenesis 
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Figures and Figure legends 
 
 
 
 
Figure 1: Zebrafish larva. Figure is representative of a zebrafish larva that is 5 days old. 
Arrows indicates the location of some major organs. Scale bar: ~ 200µM 
 
 
 
Figure 2: Use of zebrafish in genetic screens. Two forms of genetic screens exists, the first 
being a forward genetics screen, ‘phenotype to genotype’, in which a specific phenotype is 
induced and then the genes that are mutated are identified. Second is reverse genetics, in which 
mutated genes are identified or specific genes are targeted and the resulting phenotype is 
identified. 
 
Identify Mutated 
Genes 
Identify Mutated 
Phenotypes 
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Figure 3: Small molecule compound library screening in zebrafish. Fertilized zebrafish 
embryos are added to wells of a 96-well plate and compounds of interest within a library of 
compounds are added to the wells straight in the media the zebrafish are in. Parameters such 
as dose response, functions elicited by the compounds can be monitored and small molecule 
screens permits the identification of relevant targets. 
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Figure 4: Comparison between a wild-type zebrafish adult and a Casper mutant. (a) 
Representative of a normal wild-type adult zebrafish in which there is clear pigmentation, due 
to the influence from distinct classes of pigment cells, black melanophores, reflective 
iridophores and yellow xanthophores. (b) Represents a Casper mutant, which lack melanocytes 
and iridophores, which allows them to be transparent. 
 
 
 
 
Figure 5: Generation of transgenic zebrafish embryos. The most popular system for creating 
transgenic zebrafish is the Tol2 transposon system. Firstly a plasmid is created in which the 
desired protein is cloned downstream from a specific promoter and is flanked on either end (3’ 
and 5’ ends) by a minimal Tol2. Then the mRNA encoding for Tol2 transposase and the DNA 
construct are injected into the cell of a fertilized zebrafish egg. The injected zebrafish embryo 
will then have tissue specific expression of the protein, EGFP, at the integrated site. 
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Abstract 
 
Solvate ionic liquids, typically equimolar solutions of lithium bistrifluoromethylsulfonimide in 
triglyme (G3TFSI) or tetraglyme (G4TFSI) are a new class of ionic liquids with potential in 
a variety of areas such as enery storage in lithium batteries and potentially as an alternative to 
traditional organic solvents.  Herein we present the toxicity of G3TFSI and G4TFSI in an in 
vivo animal model (Danio rerio), we also present toxicity data for lithium 
bistrifluoromethylsulfonimide, bmimTFSI, along with tri- and  tetra-glyme to give context to 
the toxicity of the ionic liquids. Moreover we demonstrated that G3TFSI and G4TFSI have 
similar solvability capacity compared to DMSO to block retinoic acid synthesis during 
zebrafish embryogenesis using N,N-diethylaminobenzaldehyde (DEAB). The findings show 
that, when used in this capacity, DEAB has the same biological effect with no difference in 
off-target toxicity, validating these ionic liquids as potential replacements for DMSO. 
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Introduction 
 
The interest in ionic liquids (a salt in a liquid state) has increased dramatically over the 
past two decades.  Their use is typically claimed to have less environmental impact than 
traditional organic solvents, they are also useful as lubricants (1-5), electrolytes (6-10), 
gas capture (11), and designer solvents (12-21). The determination of how toxic ionic 
liquids are has been the focus of many studies since their popularity explosion in the 
late 20th century (22-27). The toxicity of these materials is of obvious importance with 
cellular, bacterial (28, 29) and in vivo studies being reported. For the latter studies a 
variety of animal models such as: pulmonate snails (Physa acuta), daphnia magna, and 
nematode (Caenorhabditis elegans) were used. The use of such models allows for rapid 
and cheap assessment of IL toxicity, but very few studies have been reported for toxicity 
in vertebrate models, which are much more meaningful when it comes to potentially 
harmful interactions with humans. Indeed it has been reported the toxicity profile of 
Butylmethylimidazolium chloride (bmimCl) in female Fischer rats and doses of 175 
mg/kg were well tolerated (30). Histological studies in a zebrafish model examining the 
effect of ammonium, imidazolium, pyridyl, and pyrrolidinum derived ionic liquids 
showed it was well tolerated. Toxological examination in vertebrate models is extremely 
important as these correspond well to human toxicity with the zebrafish (zf) model ideal 
due to its inexpensive and rapid means of obtaining data. Indeed this model is becoming 
increasingly popular for the rapid assessment of potential drug candidates off-target 
toxicity (31-35). 
Both cation and anion of ionic liquids can have a major effect on toxicity, the only trend 
which is fairly consistent among the studies conducted is that increasing lipophilicity of 
the cation correlates with toxicity. In addition, general imidazolium cations display the 
most toxicity, while ammonium groups are less toxic (36).  
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Due to the extensive combination of possible cations and anions possible within ionic 
liquids, there are no clear dos and don’ts of non-toxic ionic liquid design. Each new 
ionic liquid must be assessed in turn.   
In fact, the use of ionic liquids as both a means to deliver pharmaceuticals or ionic 
liquid-type groups being incorporated into active pharmaceuticals has been increasing 
in popularity in recent years (37-43). 
The focus of this study is to examine the toxicity of a new class of ionic liquids ‘solvate 
ionic liquids’ which has been recently reported as potential electrolytes in lithium ion 
batteries (44-52). Indeed the use of these solvate ILs are excellent solvents for organic 
transformations (53). Their use as a replacement for organic solvents or electrolytes in 
batteries opens up the potential for these ILs to come into human contact and so their 
toxicity is of great importance. 
Solvate ionic liquids are similar to typical ionic liquids, in that they consist of poorly 
coordinated cations and anions, though their cationic portion consists of two 
components themselves.  This makes assessment of their toxicity a slightly more 
complex task than for traditional (e.g. imidazolium) ionic liquids as each constituent of 
the cation may contribute to the toxicity, e.g. glyme, non-coordinated lithium, 
coordinated lithium, etc. 
Of interest was the assessment of the toxicity of both G3TFSI and G4TFSI, their 
constituents G3, G4, and LiTFSI (Figure 1).  The toxicity of bmimTFSI was also tested, 
with bmimTFSI a commonly used and accepted ionic liquid, while also providing a 
comparison between the chelated lithium and bmim cations.   
It should be noted that toxicity in this study was measured in three ways, (i) observed 
apoptosis in the zf embryo’s after staining with acridine orange; (ii) by examination of 
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Caspase-3 expression levels, and (iii) determination of actively cleaved Caspase-3 
protein present in the organism. 
Caspase-3 is an enzyme intimately involved with programmed cell death and is up-
regulated when living cells are under stress.  Additionally, the ‘active’ form of Caspase-
3 is cleaved from a larger zymogen and a situation may arise where the Caspase-3 gene 
is not upregulated but the active form is present within the cells at a substantially higher 
concentration, indicating imminent cell death. This situation is easily observed when 
steps (ii) and (iii) described above is carried out.  
 
Results and Discussion 
The zebrafish embryos were dosed with increasing concentrations of all test solvents in a series 
of concentrations (100, 50, 25, and 5 µM). Examination of embryos after 24-50 h hpf showed 
increasing apoptosis, stained with acridine orange, with increasing concentration (Figure 2). 
The two ethereal solvents G3 and G4 displayed similar levels of apoptosis to the solvate ionic 
liquids G3TFSI and G4TFSI. The levels of cell death were very low, with moderate apoptosis 
occurring only at the highest concentration examined (100 µM), though of the ionic liquids 
G3TFSI was less toxic than G4TFSI, albeit marginally. This was very promising when 
compared to the commercially available ionic liquid bmimTFSI, which showed high levels of 
apoptosis from at all concentrations (Figure 2). Indeed, at 100 µM the embryo had undergone 
severe developmental deformation, including minimal brain development (Figure 2).  
Previous examinations of bmimTFSI in a zf model, measuring only the lethal effect of 
this IL after 96 hpf. (54)  at a concentration of 100 mg/L (240 µM), found that this 
concentration was not fatal to the specimens. This is consistent with our studies, as the 
fish were still living though in this instance we examined the apoptosis present at lower 
concentrations which was substantial as much as 10-fold more dilute. This may be the 
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reason why previous studies noted that fish treated with ILs had reduced activity, loss 
of quilibrium, and erratic swimming among other abnormal behaviour.  Similarly, 
bmimTFSI was determined to be moderately toxic (EC50 10-100 mg/L) in assays using 
P. subcapitata, and D. magna.   
Embryos treated with LiTFSI, was the most toxic reagent examined.  In this instance very high 
levels of apoptosis were observed from as low as 5 µM, and severe growth retardation was 
observed at higher concentrations (50 and 100 µM).  Also noted was a large cluster of dead 
blood cells in the sinus venosus, though the reason for this is unknown. 
The gene expression for Caspase-3 (data not shown) was not increased in G3TFSI and G4TFSI 
exposed embryos compared to wild type embyros, and immune localization of the active 
‘cleaved’ form of caspase 3 (Figure 3). Suggesting that the ‘softening’ of the hard lithium cation 
by chelation within the glymes and anion has a very profound effect on lowering toxicity. The 
mechanism by which the lithium ion is inducing apoptosis is currently unknown, but may be 
due to the increased size of the lithium-chelate species, minimising diffusion through biological 
media. Alternatively, the introduction of such a large concentration of Li+ may cause problems 
with ion concentrations across cell membranes. 
Due to their excellent solubilising power and their low non-toxic nature, G3TFSI and 
G4TFSI were compared to DMSO, a common solubilising agent for the dissolution of 
drugs for in vitro and in vivo studies, in which G3TFSI and G4TFSI could be used to 
replace DMSO. Ideally, the ionic liquid solubilising agent would result in less 
toxicity/side effects when compared to DMSO, though even comparable results with 
similar outcomes would validate this solvent as an alternative to DMSO. To conduct 
this vehicle comparison DEAB, a known inhibitor of retinaldehyde dehydrogenase (55), 
abolishing the synthesis of retinoic acid was administered in parallel to the specimens – 
1 sample containing a DMSO only (0.1%), 1 DEAB in DMSO (10 µM) and the other 2 
 58 
 
G3TFSI co-solvent and G4TFSI co-solvent and DEAB (10 µM). Comparison of the 
treatments showed that zf embryos exposed to DEAB solubilised in either DMSO 
(Figure 4B), G3TFSI (Figure 4C), or G4TFSI (Figure 4D) from 6-30 hpf. Embyros 
displayed the reported characteristic of loss of RA signalling: lack of pectoral fin 
induction (arrowhead), shortening of the posterior head (marked by an asterix) 
malformation of the otic vesicle (arrowhead) and pericardiac edema (55-57). 
 
Conclusions 
 
The results of this work demonstrate that a concentrations up to 50 µM (or 0.5%) 
G3TFSI and G4TFSI are not toxic to zf embryos, which are more sensitive to toxicity 
than adults. Since most solvents are used at a much lower concentration (usually 0.1%) 
we can confirm that both G3TFSI and G4TFSI can safely be used as solvents. This lack 
of toxicity was demonstrated by three different complementary methods: (i) detection 
of live apoptosis by acridine orange staining, (ii) detection of the expression of a master 
gene of apoptosis: caspase 3 (iii) and detection of the active cleaved form of caspase 3 
proteins. Moreover, we also demonstrated that both G3TFSI and G4TFSI can efficiently 
be used as solvent, with comparable effect to the widely used solvent DMSO. In our 
experimental settings, G3TFSI and G4TFSI were successfully used as solvent for 
DEAB, a chemical that block retinoic acid synthesis in vivo and biologically use of 
DEAB dissolved either in G3TFSI or G4TFSI display a full penetrance of the expected 
DEAB phenotype in exposed zf embryos without inducing toxicity. Therefore, G3TFSI 
and G4TFSI are safe to use and can be used as solvent for pharmaceutical compounds 
routinely used in research laboratory. We then proposed that G3TFSI and G4TFSI can 
be used as a replacement or alternative to DMSO for experimental research in vitro and 
in vivo. 
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Figures and Figure Legends 
 
 
 
 
Figure 1: Simplified structures of solvate ionic liquids G3TFSA, G4TFSA, their 
constituents LiTFSA, G3, G4, and bmimTFSA of interest in this study. 
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Figure 2: Detection of live apoptosis with acridine orange (arrowheads in control, control 
sample is embryo exposed to no solvent) and in G3TFSA, G4TFSA, their constituents LiTFSA, 
G3, G4, and bmimTFSA of interest in this study. 
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Figure 3: Detection of cleaved caspase 3 by immune staining (arrowheads in control, the 
control sample is the embryo not exposed to solvents) and in G3TFSA, G4TFSA, their 
constituents LiTFSA, G3, G4, and bmimTFSA of interest in this study. 
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Figure 4: DEAB exposure in developing zebrafish embryos. Every embryo exposed to 
DEAB in either DMSO (B) G3TFSA (C), or G4TFSA (D) displays the characteristic of RA 
depleted embryos compared to control (DMSO exposed only (A)). 
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Abstract 
 
Solvate ionic liquids (SILs) are a new class of ionic liquids that are equimolar solutions of 
lithium bistrifluoromethanesulfonimide in either triglyme or tetraglyme, referred to as 
G3LiTFSA and G4LiTFSA, respectively. SILs play a role in energy storage lithium batteries, 
and have been proposed as potential alternatives to traditional organic solvents such as DMSO. 
G3TFSA and G4TFSA have been shown to exhibit no toxicity in vivo upto 0.5% (v/v), and 
solubilize small compounds (N,N-diethylaminobenzaldehyde) with full penetrance, similar to 
DMSO delivered DEAB. Herein, we compare the effects of storage (either at room temperature 
or -20 °C) on DEAB solubilized in either DMSO, G3TFSA or G4TFSA to investigate 
compound degradation and efficacy. The findings show that DEAB stored at room temperature 
(RT) for four months solubilized in either G3TFSA, G4TFSA or DMSO displayed no loss of 
penetrance. The same was observed with stock solutions stored at -20 °C for four months; 
however G4TFSA remained in a liquid state compared to both G3TFSA and DMSO. Moreover, 
we examined the ability of G3TFSA and G4TFSA to solubilize another small molecular 
therapeutic, the FGFR antagonist SU5402. G4TFSA, unlike G3TFSA solubilized SU5402 and 
displayed similar phenotypic characteristics and reduced dlx2a expression as reported and 
shown with SU5402 in DMSO; albeit more penetrative. This study validates the use of these 
ionic liquids as a potential replacement for DMSO in vivo as organic solubilizing agents. 
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Background 
 
In recent years, there has been an increase in the interest of ionic liquids (ILs) due to 
their potential in a myriad of chemical processes. Their unique property of being molten 
salts at room temperature imparts unusual properties such as; high ionic conductivity, 
non-flammability, and negligible vapour pressure. Due to these properties, and their 
high customisability through anion/cation pairing, have become a staple material used 
throughout a variety of disciplines (1-9). The use of imidazolium ionic liquids in drug 
delivery has seen some success, as they offer the potential to deliver sparingly soluble 
molecules via oral, or transdermal routes over a long period of time (10-17). 
Complementing this effect is the conversion of active pharmaceutical ingredients to 
ionic liquid-like salts, typically by inclusion of a charge diffuse cation or anion, which 
can result in improved therapeutic effect via changes in crystal structure (18, 19). These 
approaches have largely revolved around the use of imidazolium-derived ionic liquids 
which are a well-used and studied class of solvents. 
Of particular interest has been a new class of ionic liquids, termed ‘solvate ionic liquids’ 
(SILs), reported by Watanabe et al (20-26). The preparation of SILs is trivial, being 
simple dissolution of LiNTf2 (lithium bistrifluoromethanesulfonimide) in either 
triglyme (triethylene glycol dimethyl ether, G3) or tetraglyme (tetraethylene glycol 
dimethyl ether, G4) yields the ionic liquids, G3TFSA or G4TFSA, respectively (Fig 1). 
Recent work by our group, and others, has characterised these solvate ionic liquids using 
Kamlet-Taft parameters, and explored their use as a solvent for organic chemical 
transformations (27, 28). Recently, we demonstrated the toxicity of solvate ionic liquids 
in vivo using a zebrafish (Danio rerio), and found that both  G3TFSA and G4TFSA with 
concentrations up to 50 µM (or 0.5%) are not toxic to zebrafish embryos (which are 
more sensitive to toxicity than adults) (29). Since most organic modifier solvents (such 
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as DMSO) are used at a much lower concentration (usually 0.1%), our study was able 
to conclude that both G3TFSA and G4TFSA can be safely used as aqueous modifier 
solvents to allow evaluation of small molecules. Both G3TFSA and G4TFSA do not 
induce apoptosis at a similar concentration to DMSO (10 µM) and display a full drug 
penetrance and the anticipated physiological changes induced in the test specimens (29). 
Since these novel SILs were able to replace DMSO as organic modifiers, we were 
curious if they could be used as an alternative long term storage media for these 
molecules, and if compound degradation over this period was reduced compared to 
DMSO. 
Currently, the most commonly used organic solvent, in academic and industrial research 
laboratories, to solubilize small organic molecules in water is DMSO (30). Due to its 
ability to dissolve many kinds of compounds, DMSO plays a pivotal role in sample 
management and high-throughput screening during in vivo and in vitro evaluation.  
Due to its broad solubilizing capability and apparent low toxicity at concentrations 
<10%, (31, 32) DMSO is used as a solvent for many drug types and is used as the vehicle 
control of choice for both in vitro and in vivo studies. However, in a study coordinated 
by Corderio et al., the authors demonstrated low-dose toxicity of DMSO and concluded 
that solvents other than DMSO should be employed for solubilizing drugs (33). Thus 
there is a need to find a suitable replacement for DMSO which do not possess this 
inherent toxicity.  
Therefore, the focus and aim of this study was to evaluate the performance of the ILs 
G3TFSA and G4TFSA as a potential replacement to the conventional solvent DMSO, 
using zebrafish as a model organism. Since, we have shown the ability of G3TFSA and 
G4TFSA to solubilize DEAB with full penetrance of reported phenotypic characteristics 
(29); we wanted to evaluate the impact of storage on both G3TFSA and G4TFSA, and 
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their ability to solubilize and deliver other small molecules/pharmacological 
compounds. 
Results and Discussion 
 
To be consistent with our previous study, which used the retinoic acid synthesis inhibitor 
4-diethylaminobenzaldehyde (DEAB), we continued to use this molecule as the initial 
focus of this work.  Previous studies have shown that the prolonged storage of organic 
compounds in solution can lead to significant sample degradation, and subsequently an 
increase in the number of false positives for high-throughput biological screening assays 
(34). These false positives represent potentially erroneous investment of time and 
money elaborating on a false lead compound. As a result, many researchers and 
pharmaceutical organizations now store their organic compounds as frozen DMSO 
stock solutions in an environment of low relative humidity, to mitigate or retard 
compound degradation (34). Thus, we wanted to evaluate G3TFSA and G4TFSA’s 
ability to keep DEAB stable at RT without compound degradation or loss of efficacy. 
The rationale behind this test is that stock solutions kept at RT would remain in a liquid 
state with no concern for sample degradation from multiple freeze/thaw cycles. This 
was evaluated over a duration of four months, and differences in penetrance of the drug, 
measured by the strength of the phenotypes were determined. 
To conduct this comparison, N,N-diethylaminobenzaldehyde (DEAB), was 
administered in parallel to zebrafish embryos: one sample containing DMSO only 
(0.1%), one DEAB in DMSO and the other two, containing DEAB in either G3TFSA 
or G4TFSA. Zebrafish embryos were exposed to DEAB in the respective solvents at the 
beginning of gastrulation occurring at 6 hours post fertilization (hpf) at a final 
concentration of 5 µM. DEAB is a known inhibitor of retinaldehyde dehydrogenases 
ALDH1A1, ALDH1A2, and ALDH1A3 in mammals (teleost fish do not have an 
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aldh1a1 gene) (35). Retinaldehyde dehydrogenases convert retinaldehyde, a product 
from retinol (Vitamin A1), into retinoic acid (RA) (36). Hence, inhibiting the function 
of retinaldehyde dehydrogenases via DEAB abolishes the synthesis of RA required for 
normal growth and development (37). 
Comparison of the treatments kept at RT showed that zebrafish embryos exposed to 
DEAB solubilised in either DMSO (Figure 2b), G3TFSA (Figure 2c), or G4TFSA 
(Figure 2d) from 6–30 hpf displayed characteristics associated with the loss of RA 
signalling:(29, 38, 39). These include lack of pectoral fin induction (arrowhead), 
shortening of the posterior head (marked by an asterisk) malformation of the otic vesicle 
(arrow) and pericardiac oedema. There was no discernible differences in DEAB 
penetrance between DEAB in either DMSO, G3TFSA or G4TFSA (100% for each, n = 
60) after storage at RT for four months (29). A study conducted by Kozikowski et al., 
investigating the effect of room temperature storage on the stability of compounds in 
DMSO concluded that the relationship between length of storage and the probability of 
observing the compound is described by a repeated measures logistic regression model 
(34). Results from the study determined that the probability of observing the compound 
was 92% after 3 months of storage at room temperature, 83% after 6 months, and 52% 
after 1 year in DMSO (34). Hence, it is valuable to assess the long term effects of RT 
storage on DEAB penetrance post solubilization in both G3TFSA and GF4TFSA. 
To assess the solvate properties of G3TFSA and G4TFSA, it was also imperative to 
evaluate the performance of the ionic liquids G3TFSA and G4TFSA after storage in the 
conventional (frozen) manner. Therefore, DEAB was stored at -20 °C for 4 months in 
either DMSO, G3TFSA or G4TFSA. A comparison of zebrafish embryos treated with 
5 µM showed that zebrafish embryos exposed to DEAB solubilised in either DMSO 
(Figure 3b), G3TFSA (Figure 3c), or G4TFSA (Figure 3d) from 6–30 hpf displayed the 
 71 
 
characteristics associated with the loss of RA signalling (29, 38, 39) (100% penetrance 
for all compounds tested, n = 60). 
As previously observed in the RT test, there was an observed phenotype that clearly 
showed a lack of pectoral fin induction (arrowhead), shortening of the posterior head 
(marked by an asterisk), malformation of the otic vesicle (arrow) and pericardiac 
oedema. However, unlike both DMSO and G3TFSA, G4TFSA did not freeze at -20 °C 
but remained in a viscous state. A key characteristic of DMSO is that compared to 
G4TFSA it has a relatively higher melting point (Tm) of around 19 °C (40), hence 
DMSO freezes easily and remelts slowly at room temperature. This means that if stored 
frozen, a considerable amount of time will be spent getting DMSO (and the compound 
solubilized in DMSO) to a liquid state before it can be used. Whereas, G4TFSA was 
able to remain in a liquid like state at -20 °C, proving advantageous over DMSO as it 
can be used straight away after being removed from storage at -20 °C. Similar to DMSO, 
G3TFSA albeit higher, has a similar Tm of 23 °C (41). However, G3TFSA has a much 
higher entropy change of fusion value of 112.5 J K-1 mol-1 compared to DMSO which 
only has an entropy change of fusion value of around 50 J K-1 mol-1 (41). This means 
that even though both G3TFSA and DMSO have similar melting temperatures, G3TFSA 
will return to a liquid state much quicker than DMSO. Our 10 mL stock of G3TFSA 
stored at -20 °C took approximatively 10 minutes to melt at room temperature (around 
20°C) while it took slightly over 1 hour for the 10 mL stock of DMSO stored at -20 °C 
to completely melt at room temperature. Making G3TFSA to return to a liquid state at 
least 6 time fasted than DMSO. 
Furthermore, a study looking in to the effect of freeze/thaw cycles on the stability of 
compounds in DMSO concluded that samples that underwent freeze/thaw cycling 
suffered the most, showing a drop of more than 10% in compound efficacy within 10 
 72 
 
cycles (42), and after 25 freeze/thaw cycles tested, the percentage of compound 
remaining was 55.8% (42). Hence, since G4TFSA does not freeze at -20⁰C, there is no 
risk of compound degradation due to freeze/thaw cycles. 
With these data in hand, our attention turned to demonstrating the generality of these 
ionic liquids as a storage and delivery media for small molecular therapeutics. For the 
purpose of this study, we evaluated the ability of both G3TFSA and G4TFSA to 
solubilise and compare the performance of SU5402 (Figure 4d) a pan-fibroblast growth 
factor receptors (FGFR) specific tyrosine kinase inhibitor and is used in a multitude of 
zebrafish developmental systems to specifically inhibit FGFR signalling against DMSO 
(43-47). SU5402 is useful for assessing requirements for FGF signalling in the later 
stage of development of the zebrafish embryo because it is used late in developmental 
events such as organogenesis, leaving early FGF-dependent processes unaffected. 
Moreover, SU5402 treatment potentially uncovers FGF requirements that are not 
revealed by knocking out specific FGF ligands or receptors owing to redundancy.  
In making up the stock solution of SU5402 in the respective solvents; DMSO, G3TFSA 
and G4TFSA, it was observed that SU5402 was not soluble in G3TFSA. While the 
structure of both solvate ionic liquids is very similar, and they possess similar physical 
properties, the poly-ether used to fabricate G4TFSA possesses an extra ethylene unit 
potentially increasing the solubilising power of this liquid for small organic molecules 
(5). Hence, only SU5402 solubilized in G4TFSA was used to assess SU5402 phenotypic 
penetrance against SU5402 solubilized in DMSO. A comparison of zebrafish embryos 
treated with both SU5402 in G4TFSA at concentrations 2.5 µM (Fig 4c) and 5 µM (Fig 
4f) from 6–30 hpf displayed previously reported phenotypes, such as lack of pectoral 
fin induction (arrowhead) malformation of the otic vesicle (arrow) compared to the 
control embryo (Fig 4a). There was also an evident lack of a formed mid-hindbrain 
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boundary at concentrations of only 5 µM DEAB in DMSO and G4TFSA (open 
arrowhead) (Fig 4e, f) (39, 48).  
In addition, we wanted to the examine genes that are affected by FGF (fibroblast growth 
factor) signalling. Gibert et al., reported the formation of oral and pharyngeal dentition 
in teleosts depends on differential recruitment of retinoic acid signalling and that a lack 
of FGF signalling affects the expression of dlx2a (distal-less homeobox 2a) (49). Dlx 
genes are expressed in a coordinate manner which create proximal to distal polarity 
within the pharyngeal arches (50). In zebrafish, dlx2a is expressed in the migrating 
cranial neural which contributes to the pharyngeal arches (49-53). Hence, we 
investigated the effect on dlx2a expression using whole mount in situ hybridisation 
(WISH) after exposure to 2.5 µM SU5402 that had been either solubilized in DMSO or 
G4TFSA (Fig 5). WISH results showed that compared to the control embryos (Fig 5a, 
d), embryos treated with SU5402 solubilized in both DMSO (Fig 5b, e) and G4TFSA 
(Fig 5c, f) depicted an absence of dlx2a expression in the ventral cranial neural crest 
cells (arrows) marked by an asterix. However, comparatively there was a greater 
reduction in the expression of dlx2a (marked by AP staining) in the telencephalon 
(arrowhead) in zebrafish embryos that were treated with SU5402 solubilized in 
G4TFSA (Fig 5c, f) compared to those treated with SU5402 solubilized in DMSO (Fig 
5b, e). This indicates that G4TFSA has as greater ability to deliver SU5402 (penetrative 
power) compared to DMSO. 
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Conclusions 
 
Our data reveals that both G3TFSA and G4TFSA are comparable, at least, or slightly 
superior to DMSO in terms of compound deliverance as exhibited by the penetrance of 
DEAB and SU5402 (the latter only soluble in both DMSO and G4TFSA). This was 
evident by DEAB solubilized in G3TFSA and G4TFSA exhibiting the same phenotypic 
characteristics of DEAB made up in DMSO. SU5402 solubilized in G4TFSA and 
DMSO, reduced the expression of dlx2a in zebrafish embryos although to a greater 
extent for the latter.  However, in regards to the storage of DEAB stock solutions in 
DMSO, G3TFSA and G4TFSA in the more conventional manner at -20 °C, G4TFSA 
remained in a liquid state as it had a much lower glass-transition temperature, potentially 
realising a decreased rate of sample degradation. Consequently, G3TFSA and G4TFSA 
solubilize and deliver test/pharmacological compounds adequately and routinely in 
research laboratories, hence both G3TFSA and G4TFSA are suitable replacements for 
DMSO for experimental procedures. 
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Figures and Figure Legends 
 
 
 
Figure 1: Solvate ionic liquids and DMSO which are the focus of this study. 
 
 
Figure 2: Room temperature DEAB exposure in developing zebrafish embryos. Embryos 
exposed to DEAB at 5 µM in solution at room temperature for 4 months in either DMSO (B), 
G3TFSA (C), or G4TFSA (D) displayed the reported characteristic of loss of RA (compared 
to control (DMSO exposed only (A): lack of pectoral fin induction (arrowhead), shortening of 
the posterior head (asterisk), malformation of the otic vesical (arrow) and pericardial edema. 
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Figure 3: Frozen DEAB exposure in developing zebrafish embryos. Embryos exposed to 
DEAB at 5 µM that have been stored for 4 months at -20 °C in either DMSO (B), G3TFSA 
(C), or G4TFSA (D) display the reported characteristics of loss of RA (compared to control 
(DMSO exposed only (A): lack of pectoral fin induction (arrowhead), shortening of the 
posterior head (asterisk), malformation of the otic vesical (arrow) and pericardial edema. 
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Figure 4: SU5402 exposure in developing zebrafish embryos. Embryos are exposed to 
SU5402 (D) at 2.5 µM (B & C) or 5 µM (E & F) in either DMSO or G4TFSA display the 
reported characteristics of FGF signaling inhibition compared to control (DMSO exposed only 
(B & E)): lack of pectoral fin induction (marked by an asterisk), malformation of the otic 
vesicle (arrow. Lloss of MHB (open arrow head) was observed in embryos treated with 5 µM 
DEAB. 100X magnification. 
 
 
Figure 5: Expression of dlx2a visualized using whole mount in situ hybridization. 
Embryos exposed to SU5402 at 2.5 µM in either DMSO (B & E) or G4TFSA (C & F) display 
reduced localization and expression of dlx2a compared to control (DMSO exposed only (A & 
D) in the hindbrain (arrow) and in the pharyngeal arches (arrow head, * lack of pharyngeal 
arches). The first row depicts the embryos in a later orientation, the second row depicts the 
embryos in a ventral orientation. 
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Abstract 
 
Background: The zebrafish is a useful vertebrate model to study lipid metabolism. Oil Red-O 
(ORO) staining of zebrafish embryos, though sufficient for visualizing the localization of 
triglycerides, was previously inadequate to quantify neutral lipid abundances. For metabolic 
studies, it is crucial to be able to quantify lipid levels during embryogenesis. Currently there 
exists no cheap, rapid and reliable method to quantify the deposition of neutral lipids and 
triglycerides. Methods such as but not limited to; thin layer chromatography (TLC), gas 
chromatography and mass spectrometry can be used to accurately measure the levels of lipids 
but are time consuming and costly in their use. Hence, we wanted to develop a rapid and 
reliable method to quantify neutral lipids and triglycerides. 
Methods: Zebrafish embryos were exposed to either Rimonabant (Rimo) or WIN 55,212-2 
mesylate (WIN), compounds that both target the cannabinoid pathway and were previously 
shown to modify lipid content during zebrafish embryogenesis. Following this the yolk sac of 
the zebrafish embryo was dissected away from the zebrafish body and ORO stain was extracted 
out of both the zebrafish body and yolk sac. Optical density was then measured on the extracted 
stains to give an indication of deposited neutral lipids and triglycerides. TLC was performed 
on post treated dissected zebrafish bodies to validate the developed method for neutral lipid 
and triglyceride quantification. In addition, BODIPY FFA were also injected into zebrafish 
embryos to validate if the developed method could accurately quantify the deposition of 
exogenous neutral lipids and triglycerides accumulated due to BODIPY FFA injections.  
Results: Targeting the endocannabinoid system (ECS) during zebrafish embryogenesis 
demonstrated increased ECS activity when treated with 0.3 µM WIN, resulting in increased 
lipid accumulation. On the other hand treatment with 3 µM Rimo caused a decrease in ECS 
activity which resulted in decreased lipid accumulation. The accumulation of lipids was 
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determined by lipid staining and by quantifying the deposition of neutral lipids and 
triglycerides.  
Conclusion: Here, we have developed a reliable method that allows for the rapid quantification 
of triglycerides and neutral lipids in the developing zebrafish using Optical Density analysis. 
Previously, ORO was limited to qualitative assessment, however now ORO can be used as a 
quantitative tool to directly determine changes in neutral lipids and triglyceride levels. 
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Introduction 
 
Attempts to rapidly and reliably quantify lipids during embryogenesis are limited due to the 
lack of techniques available. The zebrafish is becoming a popular model to study lipid 
metabolism (1). One of its biggest advantages is the ability to inhibit pigmentation 
(melanogenesis) in embryos (2), which allows for the visualization of lipids. Numerous lipid 
staining methods exist to visualize the accumulation and deposition of lipids in zebrafish 
embryos and larvae such as: Sudan Black, Nile Red and Oil Red-O (ORO) staining (3-6). Sudan 
Black is utilized to stain for lipids that are present within neutrophils, whilst Nile Red stains 
for neutral lipids and triglycerides (3, 4). Despite Nile Red being able to stain for neutral lipids 
and triglycerides, it cannot be used to stain for and visualize lipids that are deposited during 
early zebrafish embryogenesis (5). Therefore, Oil Red-O staining has been shown to be a 
powerful tool in identifying the deposition of neutral lipids and triglycerides. It is a reliable 
method when investigating the deposition and the presence of these neutral lipids and 
triglycerides during early zebrafish embryogenesis (6). However, Oil Red O staining in 
zebrafish is only a qualitative measure, in which lipid deposition can only be assessed visually. 
Hence, the principle limitation in using ORO staining is that to date there is a lack of efficient 
and dependable methods that allows for the quantification of ORO staining. Methods have been 
developed that allows for the quantification of ORO staining, but only for quantifying lipids in 
vitro and on fixed histological samples. Hence, using ORO there exists no method to quantify 
neutral lipids and triglycerides in vivo during zebrafish embryogenesis. 
Here we propose a novel technique adapted for zebrafish embryogenesis that allows 
researchers to rapidly and reliably quantify the amount of ORO stain detected in the zebrafish 
embryo was examined. Correlation to the levels of triglycerides and neutral lipids present in 
the specimen. We developed this method using wild type (WT) zebrafish during early 
embryogenesis. We tested this method using two known pharmacological compounds targeting 
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the cannabinoid pathway that were previously shown to modify lipid content during zebrafish 
embryogenesis (7) Rimonabant (Rimo), a CB1 selective inverse agonist and WIN 55,212-2 
mesylate (WIN) a pan CB receptor agonist. 
The quantification method that was developed was approached having three aims in mind: 
1. Apply the quantification method we developed to examine changes in neutral lipid and 
triglyceride deposition in WT zebrafish during embryogenesis to investigate the 
changes occurring in the zebrafish body and the yolk sac as two independent systems. 
2. Examine and quantify the deposition of neutral lipids and triglycerides after the 
modulation of the endocannabinoid system (ECS). 
3. Validate the quantification of neutral lipids and triglycerides using two methods; firstly 
via a well-known method for the quantification of lipids; TLC and secondly via ORO 
after exogenous injection of BODIPY free fatty acids. 
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Results and Discussion 
 
Firstly, WT embryos that were not exposed to either Rimo or WIN during different stages of 
development (50, 72 and 96 hpf) were visualized by ORO staining (Figure 1a). From 0 hpf up 
until 5 days post fertilization (dpf), the zebrafish embryo is considered a “closed system” and 
solely relies on its yolk sac for nutrients throughout development until and early larval stage 
(which primarily consists of lipids) as it is a lecithotrophic organism (8) and won’t be able to 
commence feeding until 5 dpf.  WT embryos were then stained using ORO at 50 hpf, 72 hpf 
and 96 hpf, ORO staining was localized in the forebrain, around the eye, underneath the otic 
vesicle, and in the developing vasculature (number of biological replicates = 4, n = 10 embryos 
per biological replicate) as previously described (6) (Figure 1a). It was observed that as the 
nutrients in the yolk (as the zebrafish were progressing through development) were depleted 
the intensity and localization of the ORO stain decreased. 
To further assess changes in neutral lipids and triglyceride content, ORO stain was extracted 
from WT zebrafish embryos, in which the yolk sac was dissected intact from the zebrafish body 
(9). Quantification was then performed via optical density (OD) analysis on the body and yolk 
sac separately. As ORO stains for neutral lipids and triglycerides, OD measurements can be 
taken as a direct and correlative indication for the amount of neutral lipids and triglycerides 
that are present within the zebrafish embryo compared to a reference point or control. 
Quantification demonstrated that at 72 hpf and 96 hpf there was a 11.80% and 22.70% decrease 
in ORO staining in the body of the embryo compared to the body of WT 50 hpf embryos (n = 
10 embryos per time point, P = 0.016 and 0.045 respectively, student t-test). Moreover, at WT 
96 hpf there was a 12.35% decrease in ORO staining compared to compared to WT 72 hpf 
zebrafish embryos (Figure 1b, n = 10 embryos per time point, P = 0.000017, student t-test). 
This data fits well with the observation that ORO staining decreases as development progresses 
during early zf embryogenesis. There was no significant change in measurements from OD 
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analysis of ORO staining extracted from the yolk sac of the embryos at each studied time points 
(Figure 1c, n = 10 embryos per time point). This is explained by the fact that the yolk sac is 
dense with lipids causing ORO staining to be trapped and become saturated, even though ORO 
staining was decreasing within the body of the zebrafish embryo there was no significant 
change in the yolk sac. As a result quantification of neutral lipids and triglycerides via ORO 
staining is optimal only for changes in the embryo’s body. To confirm the reproducibility of 
this assay, we performed the same experiment over multiple replicates in 50, 72 and 96 hpf 
embryos. We were able to show that OD measurements remained consistent and uniform in 
both the zebrafish body and the yolk sac (Figure 2). This is demonstrated by the spread between 
the values for the OD measurements between each of the replicates at each respective time 
point (50, 72 and 96 hpf) for WT embryo bodies (Figure 2a), which produced a tight grouping 
of OD measurements (σ = 0.005, 0.007, 0.001, respectively). This was also observed for the 
spread of OD measurements for the yolk sacs of WT embryos at each of the subsequent time 
points (Figure 2b) (σ = 0.01, 0.01, 0.007, respectively). Demonstrating the reproducible manner 
of this assay and the accurate measure of the level of neutral lipids and triglycerides being 
deposited, and that ORO, staining can be used to repeatedly quantify neutral lipids and 
triglycerides during vertebrate embryogenesis. As the zebrafish is becoming a popular model 
in metabolic studies investigations to determine if this method of lipid quantification could be 
applied to measure physiological differences in lipid content during zebrafish embryogenesis 
was warranted. 
Increasing endocannabinoid (ECS) activity by treatment with 0.3 µM WIN, as we previously 
demonstrated caused an increase in ORO staining and expansion of the stained areas (7). While 
decreasing ECS activity with 3 µM Rimo decreased the area and intensity of ORO staining in 
the body of the embryos (7) (Figure 3a, n = 10 embryos per treatment). To confirm the changes 
in the deposition of neutral lipids and triglycerides, ORO staining was measured via OD 
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analysis (Figure 3b). Fitting with the observed overall ORO stain previously described (Fraher 
et al. 2015), Rimonabant decreased ORO staining by 16.5% (n = 10 embryos, P = 0.00005) 
and WIN increased ORO staining by 14.4% (n = 10 embryos, P = 0.000016, student t-test). 
This data draws a parallel to previous studies that have validated that Rimo decreased lipid 
accumulation in the embryos, whilst the CB1/CB2 agonist WIN brought about an increase in 
lipid deposition. A study investigating the weight-loss produced by various anti-obesity drugs 
published that rimonabant reduced weight by nearly 14% over a 28 day dosing period observed 
in the diet induced obesity (DIO) rats (10). Clinical trials conducted in 2006 across Europe and 
North America, demonstrated that Rimo produced a 10% weight loss in approximately 30% of 
the patients that were given a rimonabant dosage of 20 mg (11). 
To validate the newly developed process we injected BODIPY-labelled fatty acids into the yolk 
sac of WT zebrafish embryos at 24 hpf as depicted by the hydrophobic fluorescent lipid sphere 
(Figure 4b). Using BODIPY-labelled fatty acids allows introduction of exogenous free fatty 
acids (FFAs) into the zebrafish yolk sac during embryogenesis allows the tracking and the 
dispersion of the FFAs into and around the zebrafish body, as observed at 72 hpf (Figure 4c). 
It was evident that there was an increase for FFA in the head of the zebrafish embryo. 
Furthermore, ORO staining visually alone demonstrated that at 72 hpf  there was an increased 
localization of ORO staining in the forebrain, around the eye, underneath the optic vesicle, and 
in the developing vasculature of FFA injected embryos compared to the wild type embryos 
(Figure 4e-g) (number of biological replicates = 4, n = 10 embryos per biological replicate) 
(Figure 4h-j). Quantification via OD analysis revealed that at 72 hpf there was a significant 
increase in ORO staining in the body of FFA injected embryos compared to control embryos 
by approximately 27% ( replicates = 4, n = 10 embryos per replicate, P = 0.0279). By injecting 
FFA into the yolk sac, we were able to exogenously increase the amount of neutral lipids and 
triglycerides available to the zebrafish during embryogenesis, but were also able to accurately 
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measure the observed increase in neutral lipids and triglycerides using our quantification 
method.  
As a means of further validating the developed method for the quantification of neutral lipids 
and triglycerides, we compared lipid deposition and its composition in bodies of zebrafish 
embryos treated with Rimo and WIN from 24-50 hpf against a known method used currently 
for quantifying and analysing lipids, thin layer chromatography (TLC) lipid analysis (12-14). 
TLC allows for the measure of two parameters: changes in total lipid content and changes in 
specific classes of lipids. TLC analysis revealed that Rimo- and WIN-treated embryos yielded 
4.8 mg and 6.1 mg of total lipid content respectively, corresponding to a 21% decrease and a 
9% increase compared to the control (Figure 5a, Figure 5b, n=500 embryos per treatment 
group). Changes in total lipids present similar findings to those observed when quantifying 
ORO staining (Figure 3b). However, TLC analysis demonstrated that triglyceride levels in all 
treatment groups do not change and remained uniform (Figure 5c). Since it is known that ORO 
staining depicts the localization of triglycerides and other neutral lipids, it can be hypothesised 
that the changes in total lipid content that was observed during early zebrafish development 
(24-50 hpf) under the exposure of Rimo and WIN was not due to triglycerides but other classes 
of neutral lipids that are yet to be identified. 
 
Conclusion 
 
The development of this method demonstrates that ORO staining alone can now be used as a 
consistent and reliable method of quantifying the neutral lipids and triglycerides content during 
zebrafish embryogenesis. As a result, instead of using ORO staining solely qualitatively which 
will then need to be further investigated using other lipid analysis methods. ORO staining now 
used to provide a visual representation but it also allows the quantification of neutral lipids and 
triglycerides; ultimately saving time and resources. 
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In addition, it is important to note that the zebrafish samples that are pooled together across 
each of the replicates are consistent, i.e. they are of similar age. Embryos that are different in 
age would have varying amounts of lipids present, consequently resulting in varying degrees 
of ORO staining. For that reason, it is crucial that similar aged embryos are used in the ORO 
staining and quantification process. 
This method not only paves the way towards the application of ORO staining in measuring the 
deposition of neutral lipids and triglycerides in zebrafish during embryogenesis, but it provides 
the benefit of being utilised in an in vivo model whereas before it has been limited to, as 
previously mentioned in in vitro (15) applications and fixed histological samples (16). 
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Figures and Figure Legends 
 
 
Figure 1: Staining and quantification of neutral triglycerides and lipids in wild-type 
embryos. (a) 50 hpf, 72 hpf and 96 hpf wild-type embryos from ORO. Arrowheads are 
pointing to ORO staining around the eyes and arrows are pointing to ORO staining in the head. 
Ventral view is shown in the first column, anterior view is shown in the second column and 
posterior view is shown in the third column. (i-iii) 50 hpf, (iv-vi) 72 hpf, (vii-ix) 96 hpf. 72 hpf 
and 96 hpf embryos showed decreased ORO staining compared with 50 hpf embryos and 96 
hpf embryos showed decreased ORO staining compared with 72 hpf embryos. This figure is 
representative of 10 embryos per treatment (5 replicates with 10 embryos in each). Optical 
Density analysis of ORO stained embryos using a microplate spectrophotometer. 
Quantification took into account the intensity and amount of ORO staining present within the 
body (b) and yolk sac (c) of the zebrafish embryos. Data is represented as optical density 
measurements analysed at a wavelength of 495 nm. 72 hpf and 96 hpf embryos show a 
significant decrease in ORO staining compared to 50 hpf embryos, whilst 96 hpf embryos also 
show a significant decrease in ORO staining compared to 50 hpf embryos. Data is represented 
as the mean ± SEM of the staining for 50 embryos for 50 hpf (5 replicates with 10 embryos in 
each), 50 embryos for 72 hpf and 50 embryos for 96 hpf (n=5). *p<0.05 compared to 50hpf 
embryos, # p<0.05 compared to 72hpf embryos, @ = measured at wavelength 495nm. 
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Figure 2: Spread of OD Measurements. Optical Density analysis of ORO stained embryos 
using a microplate spectrophotometer. Quantification took into account the intensity and 
amount of ORO staining present within the body (a) and yolk sac (b) of the zebrafish embryos. 
Data is represented as optical density measurements analysed at a wavelength of 495 nm. 72 
hpf and 96 hpf embryos show a significant decrease in ORO staining compared to 50 hpf 
embryos, whilst 96 hpf embryos also show a s significant decrease in ORO staining compared 
to 50 hpf embryos. Data is represented as the mean ± SEM of the staining. Raw optical density 
data is also displayed to display the spread of optical density measurements across each of the 
5 experiments (consisting of 10 embryos each) for the body (a) and yolk sac (b). *p<0.05, @ 
= measured at wavelength 495nm. 
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Figure 3: Staining quantification for neutral triglycerides and lipids after activation of 
the ECS. (a) Embryos from ORO, treated from 24-50 hpf. Arrowheads are pointing to ORO 
staining around the eyes and arrows are pointing to ORO staining in the head. Ventral view is 
shown in the first column, anterior view is shown in the second column and posterior view is 
shown in the third column. (i-iii) Control 50 hpf, (iv-vi) 3 µM Rimo treated 24-50 hpf, (vii-ix) 
0.3 µM WIN treated 24-50 hpf. Rimo treatments showed decreased ORO staining compared 
with control treated embryos and WIN treatments depicted increased ORO staining compared 
with control treated embryos. This figure is representative of 10 embryos per treatment (n=10). 
Optical Density analysis of ORO stained embryos using a microplate spectrophotometer. 
Quantification took into account the intensity and amount of ORO staining present within the 
body (b) and yolk sac (c) of the zebrafish embryos. Data is represented as optical density 
measurements analysed at a wavelength of 495 nm. Rimo treatments show a significant 
decrease in ORO staining compared to control by 16.5%, whilst WIN treatments show a 
significant increase in ORO staining compared to control by 14.4%. Data is represented as the 
mean ± SEM of the staining for 50 embryos for control (5 replicates with 10 embryos in each), 
50 embryos for Rimo and 50 embryos for WIN (n=5). *p<0.05, @ = measured at wavelength 
495nm. 
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Figure 4: Injection of BODIPY Free Fatty Acids in to zebrafish during embryogenesis. 
At 24 hpf WT embryos were collected and FFA was injected into the yolk sac. A WT embryo 
(a) is compared to a FFA injected embryo (b) which contains a GFP tagged hydrophobic FFA 
vacuole. (c-d) Portrays the diffusion of the FFA from the yolk sac into the zebrafish body. 
ORO staining was performed on WT (e-g) and FFA injected embryos (h-k) at 72 hpf. 
Arrowheads are pointing to ORO staining around the eyes and arrows are pointing to ORO 
staining in the head. Ventral view is shown in the first column, anterior view is shown in the 
second column and posterior view is shown in the third column. At 72 hpf there was increased 
ORO staining in the FFA injected embryos This figure is representative of 10 embryos per 
treatment (4 replicates with 10 embryos in each). Optical Density analysis of ORO stained 
embryos using a microplate spectrophotometer. Quantification took into account the intensity 
and amount of ORO staining present within the body (k) Data is represented as optical density 
measurements analysed at a wavelength of 495 nm. At 72 hpf FFA injections show a significant 
increase in ORO staining compared to control by 27%. Data is represented as the mean ± SEM 
of the staining for 40 embryos for control (4 replicates with 10 embryos in each) (n=5). 
*p<0.05, @ = measured at wavelength 495nm. 
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Figure 5: Total lipid content and TLC analysis of zebrafish body. (a) Mass (mg) of total 
lipid content extracted from each of the groups; control, rimo and WIN. A decrease in total 
lipid content is observed in the rimo treatment group compared to control group, whilst an 
increase is observed in WIN treated groups. (b) Percentage change in total lipid content in rimo 
and WIN treated groups normalised to the control treatment group. (c) TLC analysis of treated 
zebrafish bodies show that the peak for the triglyceride (TAG) lipid group has a retention time 
of approximately 0.21 min. No statistical analysis was performed as there was only one 
replicate for each treatment group. Blue: Control treatment group; Red: Rimo treatment group; 
Green: WIN treatment group. 
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Abstract 
 
We conducted a 28 day feeding experiment with formulated feed using DHA-rich whole cells 
of freeze-dried marine microalgae Schizochytrium sp. to understand the distribution of fatty 
acids in a laboratory model zebrafish. We investigated three feeds such as commercial feed, 
50:50 feed (50% commercial and 50% algae) and pure algae and effect of experimental period. 
All the feeds were taken by zebrafish and showed optimal growth and weight gain, the survival 
rate was 100%. We extracted the lipids from four different tissues; brain, liver, muscle and 
blood to understand the distribution of fatty acids with respect to the feed. Maximum lipid was 
observed in zebrafish fed with 50:50 feed in all the tissues samples.  An increasing content of 
fatty acids were observed with increasing the experimental time. Algae feed supported the 
DHA accumulation in all the tissue samples compared to other feeds, this resulted in overall 
high level of PUFA. To understand the role of fatty acids during zebrafish embryogenesis, we 
collected eggs at the end of the experiment and analyzed fatty acids using gas chromatography. 
No significant difference was observed in fatty acid composition of embryos fed with algae to 
that of the available commercial feed. This provides a base for understanding of fatty acid 
distribution in zebrafish with commercial and algae feed. This results also supports the 
utilization of Schizochytrium biomass as a potential replacement for fish meal to lower the 
production cost. 
  
 102 
 
Introduction 
 
Omega-3 long chain poly unsaturated fatty acids (omega-3 LC-PUFAs) are essential fatty acids 
found in oily marine fishes. The two important omega-3 LC-PUFAs are docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA), which support heart health, normal growth and 
development (1, 2). An increasing number of studies showed the positive effects of eating fish 
in the diet, which contain protein, omega-3 fatty acids and a wide array of highly bioavailable 
micronutrients (3). However, the biggest challenge in the current society is to meet the growing 
demand by following sustainable approach. Scientific evidence shows that the catch of marine 
wild fish has begun to decline (4). Aquaculture, inland farming aquatic organisms, including 
fish, molluscs, crustaceans and aquatic plants, can play a significant role to meet the increasing 
global demand. World aquaculture production is growing steadily and has become one of the 
world’s fastest growing food production industries (5, 6). Moreover, commercialization and 
expansion of aquaculture have resulted a significant demand for fish meal (FM) and fish oil 
(FO) to feed the cultured fish. Currently, due to the limited supply and raising process the 
aquafeed industry seek alternative ingredients to meet the demand of aquafeeds for the 
foreseeable future (7). Research progress has made to replace the FM by plant-derived 
ingredients, such as soybean meal, rapeseed (canola) meal, sunflower seed meal, lupin seed 
meal, cottonseed meal, pea meal, wheat and corn widely utilized to reduce feed cost (8). 
However, plant-derived products cost may also increase due to the competition for arable land 
for food crops and the major drawback is the lack of omega-3 LC-PUFAs (9). Therefore, 
microalgae are recognized as economical and sustainable alternative source and due to their 
nutritional quality and potential availability can serve as an alternative marine-derived feed 
(10).  
Marine microalgae are the rich source of omega-3 LC-PUFAs and other wide range of 
bioactivities, including proteins, carbohydrates carotenoids with potential applications in food 
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and feed industry (11, 12). Production of biomass from phototrophic microalgae in large scale 
is an energy intensive process associated with high production costs, high technological 
development requirement, and limited production capacity (13). Nevertheless, heterotrophic 
microalgae cultivation using Schizochytrium sp. and other Thraustochytrids sp resulted in 
successful industrial-scale production of algal oil rich in omega-3 LC-PUFAs (14). 
Thraustochytrid sp, can accumulate high amount of lipids (55–75% in dry matter), typically 
contains up to 49% of total lipids of DHA (15-18). Thraustochytrid biomass as a suitable feed 
in aquaculture has been evaluated by many research studies (19-21). However, they were 
focused on replacement of fish oil with algae oils and evaluated overall lipid and fatty acid 
composition. 
In this study, we investigated three different diets such as commercial feed, algae feed 
(Schizochytrium DT3 freeze-dried biomass) and 50:50 algae and commercial feed for 
zebrafish. We studied the accumulation and bioavailability of omega-3 LC-PUFAs in zebrafish 
for 4 weeks. In this study, zebrafish was selected as a model organism to understand the 
distribution of omega-3 LC-PUFAs in the fish body. Zebrafish have been extensively used as 
model organism in nutrition and growth studies in fish. There are several advantages of using 
zebrafish such as their small size, short generation time and their capacity to produce numerous 
eggs (22). In addition to that, we also investigated the transformation omega-3 fatty acids to 
the next generation (eggs). 
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Results and Discussion 
 
Feed and growth performance  
 
We conducted a 28 day growth and lipid accumulation experiment in zebrafish (3 months old) 
with three different feeds. The experimental feed formulation and their lipid composition were 
given in Table 1. The DHA and total omega-3 fatty acid percentages in commercial feed were 
16 and 30.01, respectively. However, the DHA and total omega-3 fatty acids in algae feed were 
39.8 and 61.9, respectively. Total omega-3 fatty acid was twice the level in algae feed compare 
to commercial feed. Experimental diets were readily accepted by fish and showed the optimal 
weight gain with no mortality. The maximum weight gain was observed in feed treatment 50:50 
with 0.32 g/ fish gain in 28 days, and the lowest weight gain was observed in commercial feed 
0.07 g/fish (Table 2). The relatively high values for weight gain and growth performance in 
feed 50:50, compared pure algae feed is likely due to the low availability of protein. Our results 
for weight gain and increased growth performance with 50:50 feed treatment are in agreement 
with the previous report that the replacement of fish oil with Schizochytrium oil resulted in 
improved weight gain (27 g) (25). The possible reason is, fish are able to more efficiently 
process the algae feed which reflected in improved fish performance and weight gain. Our 
observations are similar to a recent study conducted Atlantic salmon which stimulated muscle 
or tissue development (26). The micronutrients such as carotenoid (astanxanthin) and bioactive 
compounds might have contributed in growth performance of the fish (25). Our findings are in 
consistent with recent study which demonstrates the influence of algal derived DHA on growth 
performance of in shrimp and barramundi (27). 
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Lipid accumulation in fish brain, liver, muscle and blood 
 
The total lipid content on weight basis was measured to understand the effect of diets on lipid 
accumulation in four different tissues such as brain, liver, muscle and blood. The total lipid 
content was significantly influenced by the dietary treatment (Table 3). The highest lipid 
content in brain was observed from commercial diet (33.9), which was followed by 50:50 
(24.6) and algae feed (20.6), respectively. The lipid content in liver was 2.5 folds and 5 folds 
higher in 50:50 feed treatment compared to commercial feed and algae feed treatments, 
respectively. 50:50 feed treated muscle and blood samples showed highest lipid content (10.9) 
compared to other two feed treatments. Our results are in agreement with the findings of Van 
Hoestenberghe et al.(28) that the fat content in jade perch fillet 5-6%, our current findings 
found that the fat in muscle was 7.1%. The highest lipid accumulation was observed in brain 
compared to other tissues. A recent study investigated the total lipid content in seven fish and 
found that the brain contains highest amount of lipid followed by eyes and muscle, respectively 
(29). 
Effect of time and feed on fatty acid composition of brain 
 
The fatty acid composition (% of total fatty acids) was significantly influenced by the length 
of the experiment and feed treatments.  The total SFA content of brain lipid did not significantly 
among the treatment time and feed. With the exception of feed 50:50 significant time effects 
and were higher at the end of the experiment (55%, 28 days). The SFA content in 50:50 feed 
treated brain was increased from 47% to 55% at the end of the experiment, where as in other 
treatments it was not significantly changed. One SFA, palmitic acid (16:0), showed the highest 
deposition in brain of zebrafish fed with 50:50 feed. With respect to the total MUFA content 
showed no significant change in irrespective of dietary treatment and time (Table 4).  
The total PUFAs and omega-3 fatty acids composition showed no significant change with 
respect to the diet and time interaction. The amount of DHA deposited in the brain tissue 
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significantly increased in fish fed in 50:50 from 18.5 to 20.7. However, one omega-3 PUFA, 
EPA showed highest accumulation in brain with commercial diet feed at 48 days compared to 
other diets. The absence of EPA in algae feed resulted in low level of EPA in algae fed samples, 
which suggest that EPA amount was significantly affected by feeds (30). The fatty acids present 
in the tissue reflects the fatty acid composition of the dietary feeds (31). 
 
Effect of time and feed on fatty acid composition of liver 
 
The total SFA content of the liver showed a significant difference in experiment length and 
feed treatments (Table 5). The SFA fraction of (C16, C18 and C20) varied greatly among the 
feeds and were higher in algae feed (Algae T2) at middle of the experiment (14 days) compared 
to the end of the experiment.   However, a SFA, C14 did not show significant change in the 
amount across dietary treatments and time. Palmitic acid was displayed highest percentage in 
total SFA content. The levels of MUFA (C16:1, C18:1n9, C18:1n7, C20:1) in zebrafish liver 
were significantly affected by dietary treatments and time. Zebrafish fed with algae feed 
showed the highest amount of MUFA, which was more than the MUFA in experimental diets.  
Oleic acid (C18:1n9) found to be the major MUFA in zebrafish liver irrespective of feed and 
time. A recent study recorded a significant differences in MUFA contents in fish fed on algae 
diets (30). 
Arachidonic acid (C24:4n6) and DPA (C22:5n6) were also affected significantly by feed 
treatments, highest levels were recorded in algae feed T4 and 50:50 feed T2, respectively. This 
resulted in lower levels of total omega-6-PUFA fatty acids in other feed treatments and time. 
The omega-3 PUFAs EPA and DHA displayed significant differences among dietary 
treatments and time. The EPA content was recorded highest in commercial feed treated fish 
and the DHA content was highest in only algae fed fish at the end of the experiment. Our 
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findings for high omega-3 PUFA amounts at the end of the experiments are in agreement with 
the previous reports (25). 
 
Effect of time and feed on fatty acid composition of muscle 
 
The muscle fatty acid composition was affected by different feeds and experimental time 
(Table 6). The muscle SFA fatty acid C14:0 composition did not show significant difference 
either by the feed treatment or the length of the experiment. With exception of C16 and C18, 
of all SFA displayed significant time and feed effects, and were observed in highest level at 
algae T2 and comm T0, respectively.  The muscle MUFA levels were higher in the middle of 
the experiment. The reason for low level of SFA and MUFA at the end of the experiment is the 
fatty acid composition of fish is determined the digestibility of the fatty acid intake. The total 
fat is accumulated as triglycerides (TG) in fatty fish, whereas in the lean fish, like tilapia, 
zebrafish, the muscle lipid is dominated by phospholipids (75%) (32, 33) and also being 
utilized as an energy source. The EPA content in fish muscle was overall significantly not 
affected by feeds, however, DHA was on the other hand significantly affected by feeds, with 
the highest levels in the algae T4. This resulted in overall higher content of n-3 PUFA in the 
zebrafish muscle. 
 
Effect of time and feed on fatty acid composition of blood 
 
The fatty acid composition of the blood of zebrafish also significantly aﬀected by the dietary 
treatments (Table 7). Among three feed treatments, there were no significant differences in 
total SFA acid content ranged from 615-81%. Except for C18, had significant time effects and 
generally showed a higher content at the middle (14 days) of the experiment compared to the 
end of the experiment. The total MUFA was observed with limited variation between 6%-16%, 
and highest MUFA content was found at the beginning of the experiment (T0). Thus, suggested 
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that the low levels of SFA and MUFA in blood was probably due to their use as an energy 
source (34). The EPA and DHA contents were low in among the feed treatments compared to 
the fish at the beginning of the experiment (T0). This resulted in highest level of total PUFA at 
the beginning of the experiment. The highest level of fatty acids at the beginning of the 
experiments compared to different feed treatments probably due to the distribution fatty acids 
in zebrafish.  
At the end of the experiment zebrafish embryos were collected and analyzed for the fatty acids 
composition to understand the effect of feeds on fatty acid composition of embryos. The fish 
fed with commercial feed displayed higher fatty acid composition compared to fish fed 50:50 
feed (Figure 1). The fish fed on pure algae did not lay any eggs. This suggest that the protein 
source play a major role in laying eggs. Table 8 summarizes the comparison of different algae 
used as fish feed and their potential in accumulation of omeg-3 fatty acids. Several studies 
observed the effect of feed on overall of fatty acids composition, however, the current study 
focused on the different feed treatment and effect of time on fatty acids composition in different 
fish organs.  
Conclusion 
 
This study investigated the use of microalgae biomass (Schizochytrium sp) as feed for zebrafish 
in understanding distribution of fatty acids in zebrafish. Three different feeds were formulated 
such as, commercial feed, 50:50 (commercial 50% and algae biomass 505) and pure algae 
biomass. The maximum lipid content was observed in fish fed with 50:50 feed in all different 
tissue samples. More attention was given to n3-PUFA such as DHA and EPA. The effect of 
experimental time on total lipid and fatty acids composition in four different organs brain, 
muscle, liver and blood were also investigated. Increasing contents of fatty acids were observed 
with increasing experimental time. Algae feed supported the DHA accumulation in all the 
tissue samples compared to other feeds, this resulted in overall high level of PUFA. 
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Figures and Figure Legends 
 
 
Figure 1: Fatty acid composition in adult zebrafish. Percentage of investigated fatty acids 
present in zebrafish at time points T0 (beginning of trial at 3 mpf), T2 (2 weeks into the trial), 
T4 (4 weeks into the trial) that have been fed either commercially available food, algae 
(produced biomass) or a 50% mixture of both commercially available food and the produced 
biomass. 
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Tables 
 
Table 1: Fatty acid profile of the feeds 
Fatty acids Commercial feed Algae 
biomass 
C14:0 6 10.2 
C16:0 21.2 35.2 
C16:1 4.3 2.97 
C17:0 - 8.1 
C17:1 1.6 - 
C18:0 0.3 2.8 
C18:1 22.8 0.29 
C18:3 1.4 - 
C20:1 5.4 - 
C20:4 - 0.9 
C22:0 - 0.4 
C20:5 12.7 2.9 
C24:0 - 0.4 
C22:5n6 - 6.5 
C22:5n3 1.5 19.2 
C22:6n3 16 39.8 
∑ SFAs 29.23 57.1 
∑ MUFAs 37.32 3.26 
∑ PUFAs 33.2 69.3 
∑ n3 PUFAs 30.1 61.9 
∑ n6 PUFAs - 6.5 
 
Table 2: Growth performance and feed intake 
Parameters Commercial diet 50:50 Algae  
Initial weight (g/fish) 0.63 ± 0.02  0.55 ± 0.03  0.41 ± 0.03 
Final weight (g/fish)  0.7 ± 0.07  0.87 ± 0.1  0.62 ± 0.08 
Weight gain (g/fish) 0.07 0.32 0.21 
Survival rate (%)  100 100 100 
 
Table 3: Lipid weight in four individual tissues 
Tissue Commercial diet 50:50 Algae  
Brain 33.9 ± 3.7 24.6 ± 2.1 20.6 ± 1.3 
Liver 22.1 ± 2.3 56.2 ± 23.4 10.6 ± 1.5 
Muscle 5.8 ± 1.4 7.1 ± 2.0 6.03 ± 0.9 
Blood 9.03 ± 0.4 10.9 ± 1.5 6.2 ± 1.2 
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Table 4: Percentage of individual fatty acids in brain with three dietary treatments 
Fatty acids T0 Comm T2 Algae T2 50:50 T2 Comm T4 Algae T4 50:50 T2 
C14:0 0 1.24±0.47 0.96±0.18 1.56±0.24 1.84±0.6 1.12 2.10 
C16:0 22.75 25.03 25.60 24.98±0 24.98 25.38 31.39 
C16:1 1.06 1.69 1.22 2.40 2.70 1.30 2.35 
C17:1 5.50 4.44 6.36 4.81 4.40 6.10 5.45 
C18:0 23.49 16.03 17.13 14.20 13.33 16.43 18.77 
C18:1 18.39 18.26 19.01 19.62 19.57 18.64 21.56 
C20:1 1.48 2.97 1.42 2.20 2.77 1.38 1.51 
C20:4 1.07 1.15 1.33 1.12 1.19 1.33 1.27 
C20:5 EPA 3.17 3.98 2.91 3.57 4.48 2.59 3.63 
C22:5n6 1.61 1.34 1.68 1.77 1.30 2.06 1.77 
C22:5n3 0.71 0.93 0.84 0.81 0.93 0.00 0.85 
C22:6n3 18.78 18.29 18.54 16.97 16.62 19.17 20.79 
∑ SFAs 47.26 43.38 45.51 43.31 41.76 46.16 55.71 
∑ MUFAs 27.41 30.12 29.19 30.94 31.98 28.70 32.68 
∑ PUFAs 25.33 26.50 25.30 25.75 26.27 25.15 28.30 
∑ n3 
PUFAs 
22.65 23.20 22.29 22.09 22.74 21.75 25.27 
∑ n6 
PUFAs 
1.61 3.31 3.02 3.66 3.53 3.40 3.04 
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Table 5:.Percentage of individual fatty acids in liver with three dietary treatments 
Fatty acids T0 Comm T2 Algae T2 50:50 T2 Comm T4 Algae T4 50:50 T2 
C14:0 2.17 1.76 2.44 2.34 1.85 0.00 2.99 
C16:0 31.30 35.00 43.31 34.02 29.63 34.70 32.09 
C16:1 1.52 1.79 0.00 1.53 2.33 0.00 4.40 
C18:0 26.59 15.57 24.68 16.57 12.76 20.40 9.39 
C18:1 12.22 15.77 0.00 10.41 11.28 7.42 17.30 
C20:1 2.57 1.80 3.08 1.97 3.43 2.14 1.84 
C20:4 0.00 1.21 0.00 1.67 1.79 2.74 1.11 
C20:5 5.71 6.13 3.40 4.68 7.78 5.41 5.99 
C24:0 2.04 1.47 2.32 3.36 0.90 1.53 0.37 
C22:5n6 0.00 0.00 0.00 2.68 0.84 1.91 0.50 
C22:5n3 1.27 1.55 0.00 1.48 1.42 0.00 1.59 
C22:6n3 12.25 14.83 11.09 16.18 19.04 21.97 14.40 
∑ SFAs 62.10 53.79 72.74 56.29 45.14 56.63 45.38 
∑ MUFAs 18.68 22.48 9.97 17.02 21.77 11.35 28.57 
∑ PUFAs 19.22 23.73 17.29 26.69 33.09 32.02 26.06 
∑ n3 
PUFAs 
19.22 22.51 17.29 22.34 29.30 27.37 22.66 
∑ n6 
PUFAs 
0.00 0.00 2.80 4.36 2.63 4.65 3.40 
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Table 6: Percentage of individual fatty acids in muscle with three dietary treatments 
Fatty acids T0 Comm T2 Algae T2 50:50 T2 Comm T4 Algae T4 50:50 T2 
C14:0 0.00 2.76 0.00 3.21 2.94 2.69 3.73 
C16:0 26.73 23.62 35.94 33.13 32.74 32.73 34.99 
C16:1 0 1.8 0 0 0 0 0 
C18:0 45.57 25.21 41.96 28.67 29.33 32.53 26.76 
C18:1 8.91 18.89 5.03 10.57 12.76 8.72 11.58 
C20:1 4.01 2.47 4.72 3.48 3.65 3.57 3.02 
C20:5 4.52 4.50 3.39 4.12 4.33 4.11 4.41 
C24:0 0.00 0.98 0.00 3.21 0.00 0.00 0.00 
C22:5n3 0 1.16 0 0 0 0 0 
C22:6n3 7.77 9.42 8.97 10.04 11.15 12.77 12.32 
∑ SFAs 72.30 52.57 77.89 68.21 65.00 67.96 65.48 
∑ MUFAs 15.41 25.37 9.75 17.64 19.52 15.17 17.80 
∑ PUFAs 12.29 15.08 12.35 14.16 15.47 16.87 16.72 
∑ n3 
PUFAs 
12.29 17.12 12.35 14.16 15.47 16.87 16.72 
∑ n6 
PUFAs 
0 4.93 0 0 0 0 0 
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Table 7:.Percentage of individual fatty acids in blood with three dietary treatments 
Fatty acids T0 Comm T2 Algae T2 50:50 T2 Comm T4 Algae T4 50:50 T2 
C14:0 2.15 2.03 1.92 2.24 1.78 0.00 2.78 
C16:0 26.02 33.63 35.62 33.24 33.75 36.52 35.58 
C18:0 30.86 35.68 43.86 35.53 26.41 36.28 39.87 
C18:1 9.81 7.32 2.92 4.44 7.37 4.58 4.77 
C20:1 3.33 3.86 4.45 3.27 3.90 3.71 3.87 
C20:5 6.49 4.46 4.06 3.01 6.74 4.30 3.61 
C20:3n6 H 
GLA 
0.00 2.16 2.28 1.55 1.30 1.84 2.41 
C22:6n3 14.15 6.32 5.90 7.30 14.20 12.49 8.64 
∑ SFAs 59.03 71.35 81.40 71.02 61.94 72.79 78.22 
∑ MUFAs 16.48 13.69 7.36 7.71 14.43 8.28 8.64 
∑ PUFAs 24.48 14.96 12.24 11.86 23.63 20.59 14.65 
∑ n3 
PUFAs 
22.46 10.79 9.95 10.31 22.34 18.75 12.24 
∑ n6 
PUFAs 
2.03 4.17 2.28 1.55 1.30 1.84 2.41 
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Table 8:.Comparison of different algae as a fish feed and their fatty acid accumulation 
Fish type Algae Algae 
used 
in 
feed 
(%) 
Time 
(weeks)/Un
its 
measured 
EPA  DHA  ∑ n-3 
fatty 
acids  
Referenc
es 
Atlantic 
salmon 
Phaeodactyl
um 
tricornutum 
6 8/ (g in 100 
g sample) 
0.6wb 1.3wb 2.7wb [21] 
Atlantic 
salmon 
Schizochytriu
m sp 
10 
60 
12/g/kg 
fillet 
12 
3·36  
12·20 
 
22·5 
[17] 
Epinephel
us 
lanceolat
us 
Schizochytriu
m limacinum 
FM10
0 
FM20 
FM60 
12/g 100 g-1 
FAME 
7.3  
25.8 
 
 
33.6 
[18] 
Atlantic 
salmon 
Schizochytriu
m sp 
11% 
5.5% 
 
19/% of 
total lipid 
2.9  
8.9 
18.9 [19] 
Atlantic 
Salmon 
Entomoneis 
sp 
5 12/mg/g of 
lipid 
2.7wb 
2.7F 
6.1wb 
7.5F 
12.2
wb 
13.5F 
[22] 
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Zebrafish Schizochytriu
n DT3 
50:50 4/% of lipid 3.63B (T4) 
5.9L(50:50
T4)  
4.11M(AT
4) 
20.79B 
(T4) 
21.97L 
(AT4) 
12.77M(A
T4) 
 
24.4
2 
27.8
7 
16.8
8 
This 
study 
B: Brain, L: Liver, M: Muscle, AT4, Algae T4 
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Chapter 6 
 
Discussion and Future Directions 
Chapters 2 and 3 
 
Ionic liquids have permeated many areas of chemistry, biology, materials science, and are 
prevalent in industrial applications. They are commonly advocated for their negligible vapour 
pressure, solubilising ability, and their excellent application to organic synthesis. It wasn’t until 
recently a range of novel solvate ionic liquids (SILs) was developed as potential electrolytes 
for lithium ion batteries; however their potential application as an alternative to both traditional 
organic solvents (such as the widely used DMSO) remained unknown. Using zebrafish as an 
in vivo model we investigated the capacity of the SILs G3TFSA and G4TFSA to act as solvents 
to deliver small compounds, as well as assess their toxicity profile.  
Firstly, assessing the toxicity I was able to demonstrate that both G3TFSA and G4TFSA are 
not toxic to zebrafish embryos at concentrations up to 0.5%. Solvents such as DMSO are used 
at lower concentrations, usually around 0.1%, therefore we can confirm that both G3TFSA and 
G4TFSA can be safely used as solvents. Furthermore, gauging toxicity in vivo provides better 
insight to the toxicity profile of the SILs as it is an assessment attained based on whole 
organism interaction compared to LC50 values obtained from in vitro studies, as most in vitro 
studies are specific cell line based. However, LC50 values provide a valuable starting point 
when it comes to establishing a toxicity dose response profile in vivo.  
To follow this study, I next assessed whether both G3TFS and G4TFSA can be used to 
successfully deliver small compounds in vivo. For this study we used the compounds DEAB 
and SU5402; inhibitors of retinoic acid synthesis and FGFR signalling respectively. These two 
small compounds were chosen as we have previously described their phenotypes observed 
when administered to zebrafish using DMSO as a vehicle. Hence, I was able to make a direct 
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comparison between DMSO and both G3TFSA and G4TFSA based on observed results. In the 
study I was able to show that both G3TFSA and G4TFSA are comparable, or slightly superior 
to DMSO in terms of compound deliverance as exhibited by the penetrance of DEAB and 
SU5402 (the latter only soluble in both DMSO and G4TFSA). This was evident by DEAB 
solubilized in G3TFSA and G4TFSA exhibiting the same phenotypic characteristics of DEAB 
made up in DMSO. SU5402 solubilized in G4TFSA and DMSO, reduced the expression of 
dlx2a in zebrafish embryos although to a greater extent for the latter. In order to get a more 
accurate understanding into whether these SILs can be used clinically we will need to continue 
our studies in adult and mammalian models. Even though zebrafish provide an adequate 
starting point, the efficacy and penetrance of G3TFSA and G4TFSA would need to be assessed 
in a mammalian model which would share more homology to humans. Furthermore, by using 
these models, we could look into more reported effects known to be caused by these treatments. 
Furthermore, in order to fully establish whether G3TFSA and G4TFSA can be used as 
replacement organic solvents, I feel that efficacy to deliver a wide range of compounds and 
therapeutics needs to be assessed. The best way to do this would be to use an established 
drug/compound library which has an established and comprehensive account of observed side 
effects and phenotypes. I also believe in order to completely utilize both G3TFSA and G4TFSA 
their chemical/ molecular structures should be analysed by way of NMR to see what classes of 
compounds and therapeutics best interact with the structure of these SILs. This area is out of 
my scope of expertise, but can be achieved by utilising the skill set of organic chemists. 
 
Chapters 4 and 5 
 
As I have previously stated, Oil Red-O staining has been shown to be a powerful tool in 
identifying the deposition of neutral lipids and triglycerides. It is a reliable method when 
investigating the deposition and the presence of these neutral lipids and triglycerides during 
early zebrafish embryogenesis. However, ORO staining in zebrafish was previously only a 
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qualitative measure, in which lipid deposition can only be assessed visually. As a consequence, 
I developed a method using ORO staining to quantify neutral lipids and triglycerides in vivo 
during zebrafish embryogenesis. The developed method allows researchers to directly correlate 
the levels of triglycerides and neutral lipids present in the specimen. As discussed (chapter 4) 
this method is based on the principle of optical density, in which absorbed light is measured in 
the extracted ORO samples; the more ORO stain present in a given sample the higher the OD 
reading would be. This then gives an arbitrary value which can be used to assess the abundance 
of neutral lipids and triglycerides present compared to the control sample. However, it is 
important to note, for this method to be accurate, zebrafish samples that are pooled together 
across each of the replicates are consistent, i.e. they are of similar age. Embryos that are 
different in age (and subsequently size) would have varying amounts of lipids present, 
consequently resulting in varying degrees of ORO staining. For that reason, it is crucial that 
similar aged embryos are used in the ORO staining and quantification process. 
In developing this method I used two pharmacological compounds that our lab has previously 
shown to modify lipid content during zebrafish embryogenesis, therefore I would be able to 
reliably know if the method I had developed was in fact accurate and consistent with previous 
knowledge. The method was validated using another known method of lipid quantification, 
TLC, however is much more rapid and cost effective than TLC and other known methods of 
lipid quantification. This method can be applied to rapidly and reliably investigate the relative 
abundance of neutral lipids and triglycerides after chemical modulation or pharmacological 
influence. Even though this method only gives an accurate indication as to the relative amount 
of lipids present in a given sample, it can be used as a proof of principle/precursor experiment 
to establish a dose response before performing experiments to investigate and establish a 
comprehensive lipidomic profile. This method can also be used to establish a profile of lipid 
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abundance for currently known as well as novel compounds and drugs that target lipid 
metabolism. 
The assessment of algal biomass as fish feed was indeed somewhat different from the prior 
section, as it was not focused on chemical modulation of lipids, but rather the use of a novel 
microalgae biomass as feed for zebrafish in understanding distribution of fatty acids in 
zebrafish. This study supports the utilization of Schizochytrium biomass as a potential 
replacement for commercially available fish feed to lower the production cost whilst still 
proving omega-3 fatty acids and a wide array of highly bioavailable micronutrients. This study 
could have equal impact on the aquaculture industry as well as an impact on health care.  
To follow my study, the effects of fatty acid distribution using this biomass feed should be 
investigated in more sustainably farmed aquaculture fish species such as salmon and cod etc., 
to see if the same distribution of fatty acids is observed It would also be of immense value to 
assess this algal biomass as a supplementation in a mammalian model that is homologous to a 
human system, to investigate if capsulated whether the biomass would alter fatty acid 
distribution in a beneficial manner. Currently supplements such a fish oil exists that have been 
manufactured from farmed aquaculture, however, I believe it would be far more sustainable 
and cost effective if an algal biomass (such as this) could be used to distribute omega-3 LC-
PUFAs such as DHA and EPA directly to the person.  
 
As a whole, I feel that my studies have not only made an impact on the field of biology, but 
somewhat also in a health setting. I have expanded the knowledge surrounding both drug 
discovery and target validation using a novel organic solvent as a compound vehicle. I have 
also created a foundation of information and a novel method to understand lipid profile and 
abundance in zebrafish embryos throughout development. Finally, I have elucidated the effects 
of a novel algal biomass as fish feed in positively influencing the distribution of fatty acids 
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such as DHA and EPA. I firmly believe, these studies should positively influence both 
scientific and clinical studies. 
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Chapter 7 
 
Chronological Summary of Methods 
 
Animal Use 
 
The Deakin University subcommittee on Animal Welfare and Ethics, under protocol G17-
2015, approved Zebrafish studies. Zebrafish embryos were collected from the spawn of WT 
zebrafish (strain AB) from an aquatic habitats fish facility at the Deakin University upper 
animal house. Zebrafish were maintained according to normal zebrafish husbandry procedures. 
Chapter 2 
Acridine Orange staining 
 
Live embryos were stained for apoptotic cells with the vital dye acridine orange (Sigma-
Aldrich) marking apoptotic cells, as described by Chan and Cheng et al (1). Images were taken 
using the Axioimager (Zeiss) and processed with Adobe Photoshop software. 
Cleaved caspase 3 antibody staining 
 
Cleaved caspase 3 labelling was performed with BD Pharmigen™ caspase 3, Active Form 
antibody (BD Biosciences North Ryde, Australia) and Donkey anti-Rabbit IgG (H+L) 
secondary antibody, Alexa Fluor® 488 (Life Technologies Mulgrave, Australia) as described 
by Sorrells et al (2).  
DEAB treatments of zebrafish embryos 
 
N,N-diethylaminobenzaldehyde (DEAB) (Sigma, MO,USA), was dissolved in different 
solvent: DMSO, G3TFSI and G4TFSI  at a concentration of 10 mM at room temperature. After 
vortexing, a 1/1000 dilution was used to exposed zf from 6 to 30 hpf in the dark. Live imaging 
were performed at 30 hpf. 
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Chapter 3 
Chemical Treatments 
 
N,N-Diethylaminobenzaldehyde (DEAB) (Sigma, MO, USA) and SU5402 (Sigma, MO, USA) 
were dissolved in different solvents: DMSO, G3TFSA and G4TFSA at a concentration of 10 
mM. This concentration was chosen based on our previous published data on the toxicity of 
these solvents [29]. Stock solutions on 10mM were kept stored in either -20⁰C or RT (only 
DEAB stocks) depending on the application. After vortexing, appropriate volumes were used 
to expose zebrafish embryos from 6 to 30 hpf in the dark. Live imaging was performed at 30 
hpf. 
Whole mount in situ hybridisation 
 
Embryos were fixed in 4% PFA-PBST overnight at 4°C and then transferred to and stored in 
100% methanol at -20°C. Whole-mount in situ hybridization using digoxigenin-labeled 
riboprobes was performed as previously described.(3) Using distal-less homeobox 2a (dlx2a) 
as a probe, whole-mount in situ hybridization was performed on at least 20 embryos (10 treated 
embryos and 10 control embryos) 
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Chapter 4 
Compounds and Treatments 
 
Zebrafish embryos were treated between the time frames of 24-50hpf with the following 
compounds: 
WIN 55,272-2: (WIN) (Cayman Chemicals- [2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone 
mesylate, cat# 10009023). Working solution was made up in 100% Dimethyl Sulfoxide 
(DMSO) (Sigma, cat# W387509) and stored at -20°C. 
Rimonabant (Rimo): (Cayman Chemicals- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide, cat# 9000484). Working solution was 
made up in 100% Dimethyl Sulfoxide (DMSO) (Sigma, cat# W387509) and stored at -20°C. 
For treatments 25 zebrafish embryos were placed in 50mL DB BPA free Flacon tubes and then 
topped up to 25mL with E3 zebrafish water. Embryos were either treated with 3µM Rimo or 
0.3µM WIN and control (wild-type) (treated at; 24-50hpf, 50-72hpf and 72-96hpf) embryos 
were treated with DMSO alone (compound vehicle).  250µL of PTU (1-Phenyl-2-thiourea) 
(Sigma Aldrich, cat# 7629) was then added to each tube to prevent pigment formation. Tubes 
were then incubated at 28°C ±1°C for the required time periods. Embryos were then 
dechorionated before being fixed in 4% PFA (Sigma, Paraformaldehyde, Polyoxymethyleneat, 
cat# 158127) and stored at 4°C. 
 
Oil-Red O (ORO) Staining 
Stock Solution  
Add 0.5g of Oil Red O (Sigma- 1-([4-(Xylylazo)xylyl]azo)-2-naphthol, cat# O0625) add to 
100ml 100% isopropanol (AnalaR NORMAPUR, cat# 20842.330). Stirred overnight on a 
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magnetic stirrer at room temperaturert and then filtered using 0.2µM Whatman filters 
(Whatman, cat# 1202125). Stored at 4°C. 
Working Solution  
Stir ORO stock solution for 5-10 min before taking aliquot. Mix 1 part ORO stock to 1 part 
10% isopropanol (in MilliQ water). Mix and let sit at rt for 20 min before use. 
Staining 
Rimo and WIN treated (24-50hpf) embryos and control (WT; 24-50hpf, 50-72hpf and 72-
96hpf) embryos that were fixed in 4% PFA at 4°C overnight were washed with 60% 
isopropanol for 1 h. 60% isopropanol was discarded and was replaced with 1 mL of ORO 
working solution (0.25% ORO stock in 60% isopropanol) for 1 h and 15 min. ORO solution is 
then discarded and embryos are washed quickly (30 sec) with 60% isopropanol. Then rinsed 
again for 3 min in 60% isopropanol, followed by a 30 sec was in 0.1% PBTw (PBS with 0.1% 
Tween 20 (Sigma- Polyoxyethylenesorbitan monolaurate, cat# P1379). ORO stained fish go 
through a series of glycerol (Chem-supply, 1,2,3-Propanetriol, cat# GA010) washes prior to 
storage; 30% glycerol (made up in PBTw), 50% glycerol and 75% glycerol, each for 15 min at 
rt. Embryos are then stored in 75% glycerol at 4°C. 
 
ORO Extraction and Quantification 
Rimo and WIN Treated zebrafish embryos were dissected in order to dissect the yolk sac away 
from the body and were stored in separate 1.5mL Eppendorf tubes. Sample sizes of 10 embryos 
were pooled together per Eppendorf tube in order to extract adequate volume of ORO stain. 
Replicates for each treatment group ranged from 4-8 Eppendorf tubes. E3 zebrafish water was 
then removed from each Eppendorf tube leaving just the zebrafish body or the yolk sac and 
then 250µL of 4% v/v Igepal CA-630 (Sigma- Octylphenoxy poly(ethyleneoxy) ethanol, cat# 
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I8896) (can substitute with Nonidet P-40 (Octylphenoxy poly(ethyleneoxy)ethanol) made up 
in 100% isopropanol was added to each Eppendorf tube. Samples were briefly mixed in a 
vortex machine (Vortex Genie 2, Scientific Industries Inc., Bohemia, N.Y, 11716, USA, 
Laboratory Equipment, and Model G-560E) and incubated at rt for 2 h until the zebrafish bodies 
and yolk sacs were lacking any ORO staining (tissue goes visibly white), indicating all the 
ORO stain has been completely extracted into solution. 200µL of the solution that contained 
the extracted ORO stain was then pipetted into respective wells of a 96-well plate and 
OD(absorbance) was read on a X-Mark Microplate Spectrophotometer (Bio-Rad) at 495nm 
with an initial plate shake of 5 seconds, using the Microplate Manager© 6 Software (Bio-Rad 
Laboratories, Inc, 2000 Alfred Nobel Drive, Hercules, CA 94547, USA©, 2008 Bio-Rad 
Laboratories, Inc). OD measurements of ORO stained embryos were then normalised to OD 
measurements of non ORO staining zebrafish embryo bodies.  
ORO Imaging 
Zeiss microscope axioshop with an axiocam digital camera and AxioVision Rel 4.8 software 
was used to take images of ORO stained zebrafish embryos at magnification 100X. 
 
Zebrafish lipid extraction and analysis  
Lipid extraction 
Rimo and WIN treated zebrafish embryos as well as control embryos were dissected in order 
to dissect the yolk sac away from the body as only the bodies are required, to give an average 
yield of 10mg of dried lipid sample. Total lipids were extracted according to the Bligh and 
Dyer method (4) with slight modifications. For lipid extraction, 10-20 embryo bodies were 
pooled. Zebrafish were transferred to a microfuge tube in minimal media and 200µl of 
homogenization buffer (20 mM Tris, 1 mM EDTA) was added. The embryos were then 
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homogenized by hand using a mini-pestle and 750 µl of chloroform: methanol (1:2) was added 
to the homogenate, followed by 250 µl of chloroform and 250 µl of homogenization buffer. 
Samples were vortexed for 30 sec after the addition of each extraction reagent. Samples were 
incubated at ~25°C for ~5-10 min and centrifuged at 3000 g for 5 min. The organic phase was 
transferred to a clean microfuge tube. The organic phase was then purified using authentic 
upper phase, which is prepared the same way as above, however the sample is substituted for 
distilled water, 450 µl of authentic upper phase is added to the previously collected organic 
phase and the samples are incubated at ~25°C for ~5-10 min and centrifuged at 3000 g for 5 
min. The organic phase is then collected and transferred to a clean microfuge tube and stored 
at −80°C. 
 
Drying lipid samples 
Sample in the 10 mL glass screw cap tube that was obtained from the lipid extraction process 
is placed in the water bath heating system which was attached to the N-EVAP TM III Nitrogen 
Evaporator (Organomation Associates, Inc. Berlin, MA, 01503, USA). Tubes were placed in 
the apparatus (held in place by springs) and the nitrogen needles were lowered so that they 
were above the sample liquid but not in the liquid. Nitrogen needles were cleaned with 
dichloromethane:methanol (DCM:MeOH) prior to use. Samples were dried using nitrogen gas 
until samples were completely dry. Samples were then reconstituted in hexane in order to be 
analyzed via thin layer chromatography (TLC). 
Thin layer chromatography analysis of lipids present 
Extracted oil samples are analysed by capillary chromatography with a flame ionization 
detector (Iatroscan MK5, Iatron Laboratories Inc., Tokyo, Japan), as described in Byreddy et 
al., 2016 (5). 
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Free Fatty Acids Injections and imaging  
Preparation of Free Fatty Acids for Injection 
BODIPY-labelled Free Fatty Acids ((BODIPY® FL C12 4,4-Difluoro-5,7-Dimethyl-4-Bora-
3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid) (Thermo Fisher Scientific, cat# D-3823) were 
constituted in commercially available olive oil to a final working concentration of 1 µg/µl. An 
insulin injection needle was used to load the FFA into a glass capillary injection needle with 
an outside diameter of 1 mm. The injection needle was then placed into a tabletop centrifuge 
and spun at 150-500 rpm at 10 sec intervals until the FFA settled at the needle tip.  
Injection of Free Fatty Acids 
Preloaded glass capillary injection needles were loaded into the MPPI-2 pressure injector 
(Applied Scientific Instrumentation, Oregon, United States). Approximately ~2 ng of 
conjugated BODIPY-labelled Free Fatty Acids was injected into the yolk sac of 24 hpf 
anesthetized (4mg/ml Tricaine, Sigma Aldrich, cat# E10521)) zebrafish embryos (remained 
inside chorion) as previously described (6). 
Imaging of injected of Free Fatty Acids zebrafish embryo 
Imaging of FFA injected zebrafish embryos was performed on the ZOE fluorescent cell imager 
(Bio-Rad Laboratories, Inc, Victoria, Australia). At 20X magnification under a GFP filter at 
specifications; Gain: 40, Exposure: 100, LED Intensity: 40, Contrast: 26.  
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Statistical Analysis 
 
When possible, ORO extraction experiments were completed using 5 replicates with 10 
zebrafish embryos per replicate and FFA injections using 4 replicates with 10 zebrafish 
embryos per replicate to facilitate statistical analysis. Rimonabant and WIN-552272-2 treated 
groups were each compared with the control group and WT 72 hpf and WT 96 hpf were 
compared with WT 50 hpf, whilst WT 96 hpf was also compared with WT 72h pf, using SPSS 
software (version 22.0; Fullerton, USA). OD (optical density) data for each of the treatments 
including the ORO stained control group was normalized to the data of the non-ORO stained 
control group. Statistical analysis of BODIPY FFA injection experiments were performed as 
described above using SPSS software. Independent sample t-test analysis was used assess the 
difference in OD between the treatment groups and the ORO stained control groups; translating 
to a difference in lipid deposition between the treatment groups and the control group. Data 
was significant if p<0.05. 
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Chapter 5 
Production of Biomass 
 
The biomass was produced according to the previous study (7). Schizochytrium sp. DT3 (an 
in-house isolate), used in this study were maintained on GYP medium consisting of glucose 5, 
yeast extract 2, mycological peptone 2, agar 10 g L−1 and artificial seawater 50%, at 25 °C and 
sub-cultured after 15 days. Seed medium (1% glucose, 0.2% yeast extract, 0.2% mycological 
peptone, ASW 50%, pH 6.5) and production medium (4% Glycerol, 1% yeast extract, 0.1% 
mycological peptone, ASW 50%, pH 6.5) were autoclaved at 121 °C for 20 min. Seed medium 
(50 mL) was inoculated from agar plates and grown for 2 days in a shake flask at 25 °C, at 150 
rpm. Inoculum (5%) was used to inoculate production medium and incubated under the same 
conditions for 5 days. Biomass was harvested by centrifugation (10,000g, 15 min) and washed 
twice with distilled water, then freeze-dried for 24–48 h. Freeze-dried biomass was stored at -
20 oC for further use. 
Feeding Protocol 
 
Three experimental groups were setup: commercial diet (normal zebrafish diet), diet solely 
consisting of produced biomass at the same weight of commercial diet and a 50:50 mix by 
weight of commercial food and biomass. Zebrafish are fed twice per day.  
Zebrafish BMI measurements 
 
The length (cm) and bodyweight (g) of zebrafish were measured before the study began at T0 
and then subsequently every two weeks at T2 and T4 at which the study ended. The length of 
zebrafish was determined from the tip of the nose till the start of the tail fin. BMI was calculated 
as g/cm2. 
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Lipid analysis of zebrafish tissue 
Dissection of zebrafish tissue and collection of whole blood 
3 zebrafish from each of the dietary groups at each time point were carefully collected and 
anesthetised in 0.00002% benzocaine hydrochloride. Whole blood was collected according to 
the protocol presented by Pedroso et al., 2012 and stored at -80oC; approximately 10 µl from 
each individual fish was obtained. Since whole blood was required for further analysis, the 
blood was not centrifuged to obtain blood plasma or serum. Once blood was collected, 
zebrafish were decapitated at the base of the head and were bathed in ringer solution (116 mM 
NaCl, 2.9 mM KCl, 1.8 mM CaCl2, 5.0 mM HEPES, pH 7.2). The brain and liver were then 
dissected out of zebrafish as described in Gupta et al., 2010. Skeletal muscles were excised 
from zebrafish near the anal fin. Harvested brains, liver and muscle were snap frozen in liquid 
nitrogen and then stored at -80oC. 
Lipid extraction 
Total lipids were extracted according to the Bligh and Dyer method (8) with slight 
modifications. For lipid extraction, 200µl of homogenization buffer (20 mM Tris, 1 mM 
EDTA) was added to the frozen whole blood, brain, liver and skeletal muscle samples. The 
tissues were then homogenized by hand using a mini-pestle and 750 µl of chloroform: methanol 
(1:2) was added to the homogenate, followed by 250 µl of chloroform and 250 µl of 
homogenization buffer. Samples were vortexed for 30 seconds after the addition of each 
extraction reagent. Samples were incubated at ~25°C for ~5-10 minutes and centrifuged at 
3000 g for 5 minutes. The organic phase was transferred to a clean microfuge tube. The organic 
phase was then purified using authentic upper phase, which is prepared the same way as above, 
however, the sample is substituted for distilled water, 450 µl of authentic upper phase is added 
to the previously collected organic phase and the samples are incubated at ~25°C for ~5-10 
minutes and centrifuged at 3000 g for 5 minutes. The organic phase is then collected and 
transferred to a clean microfuge tube and stored at −80°C. 
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Drying of extracted lipid samples 
Organic phases obtained from the lipid extraction process are placed in the water bath heating 
system which was attached to the N-EVAPTM III Nitrogen Evaporator (Organomation 
Associates, Inc. Berlin, MA, 01503, USA). Tubes were placed in the apparatus (held in place 
by springs) and the nitrogen needles were lowered so that they were above the sample liquid 
but not in the liquid. Nitrogen needles were cleaned with dichloromethane:methanol 
(DCM:MeOH) prior to use. Samples were dried using nitrogen gas until samples were 
completely dry.  
Fatty acid analysis of extracted lipids 
Extracted lipids were converted to fatty acid methyl esters (FAMEs) by acid-catalyzed trans-
esterification with minor modifications (Christie and Han, 2010). 1 ml toluene was added to 
the tube followed by the addition of 200 µl of internal standard, methyl nonadecanoate (C19:0) 
and 200 µl of butylated hydroxytoluene (BHT). Acidic methanol (2 ml) was also added to the 
tube and kept for overnight incubation at 50 °C. Fatty acid methyl esters (FAMEs) were 
extracted into hexane. The hexane layer was removed and dried over sodium sulphate. FAMEs 
were concentrated using nitrogen gas. The samples were analyzed by a GC-FID system 
(Agilent Technologies, 6890N, US). The GC was equipped with a capillary column 
(Supelcowax 10, 30 m × 0.25 mm, 0.25 µm thickness). Helium was used as the carrier gas at a 
flow rate of 1.5 ml min-1. The injector was maintained at 250 °C and a sample volume of 1 µl 
was injected. Fatty acids peaks were identified by the comparison of retention time data with 
external standards (Sigma-Aldrich, Australia). Peaks were quantified with Chemstation 
chromatography software (Agilent Technologies, US). 
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Statistical analysis  
 
All the results were represented as mean of three samples replicates ± standard error (n = 3, N 
= 21). After testing the normality and homogeneity of variance, statistical analysis was 
performed using the one-way analysis of variance (ANOVA) and differences between 
treatments means were determined by Student-Newman-Keuls Post-hoc test, with significance 
accepted at P < 0.05. All statistical analyses were performed using IBM SPSS Statistics v24.01 
(SPSS Inc. Chicago, IL, USA).  
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